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ABSTRACT 
Protein kinases and phosphatases play important roles in the phosphorylation state of intracellular 
proteins under both physiologic and pathophysiologic conditions. Compared to the large number of 
studies investigating the significance of kinases, in particular the mitogen-activated protein kinases 
(MAPKs) in myocardial ischaemia/reperfusion and ischaemic preconditioning, relatively few studies 
have been done on the protein phosphatases in this scenario. Although several role players in the 
signal transduction cascade of ischaemia/reperfusion and ischaemic preconditioning have been 
identified thus far, the exact mechanism of cardioprotection still remains unclear. 
 
Previous studies from our laboratory have shown that the stress kinase, p38 MAPK, has a dual role 
in preconditioning: it acts as trigger of the process, while attenuation of its activation during 
sustained ischaemia and reperfusion is required for cardioprotection. Since the activation of p38 
MAPK is dependent on both the upstream kinases for phosphorylation and phosphatases for 
dephosphorylation, we hypothesized that the balance between the activation state of the MAPKs 
and the induction of phosphatases may play a major role in determining the fate of cardiomyocytes 
exposed to ischaemic stress.  
 
The objectives of this study were: (i) to assess the activity of the myocardial protein phosphatases 
(PSPs and PP1) during sustained ischaemia and during reperfusion of non-preconditioned and 
ischaemic preconditioned hearts; (ii) to evaluate the significance of these phosphatases in 
ischaemia/reperfusion as well as in ischaemic preconditioning using available appropriate inhibitors; 
(iii) to give particular attention to the role of the phosphatase, mitogen-activated protein kinase 
phosphatase-1 (MKP-1), in ischaemia/reperfusion. MKP-1 is upregulated by stress conditions and 
selectively inactivates p38 MAPK by dephosphorylation of the regulatory Thr and Tyr residues. The 
glucocorticoid, dexamethasone which increases MKP-1 expression, was used as agonist to 
upregulate MKP-1 experimentally.  
 
The isolated perfused working rat heart was used as experimental model. After stabilization, hearts 
were subjected to either a one-cycle or multi-cycle ischaemic preconditioning protocol, followed by 
sustained global or regional ischaemia and reperfusion. Non-preconditioned hearts were subjected 
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to ischaemia/reperfusion only. For Western blot analysis of MAPKs, PKB/Akt and MKP-1, hearts 
were freeze-clamped at different times during the perfusion protocol. Endpoints were infarct size, 
functional recovery and phosphorylation of the MAPKs (ERK and p38 MAPK) and PKB/Akt during 
reperfusion. Expression of MKP-1 was monitored.  
 
The results obtained showed that activation of PSPs and PP1 does not occur during sustained 
global ischaemia or reperfusion of non-preconditioned and preconditioned hearts. The role of the 
phosphatases was subsequently further investigated using two inhibitors namely cantharidin (5 μM, 
a concentration which inhibits both PP1 and PP2A) and okadaic acid (7.5 nM, a concentration 
which inhibits PP2A selectively). Administration of cantharidin or okadaic acid during the 
preconditioning phase, completely abolished preconditioning induced cardioprotection as indicated 
by mechanical failure during reperfusion and increased infarct size, associated with increased 
phosphorylation of p38 MAPK and PKB/Akt and dephosphorylation of ERK42/44. These results 
suggest a role for PP2A in the trigger phase of preconditioning. Administration of cantharidin or 
okadaic acid during early reperfusion of preconditioned hearts improved functional recovery. This 
was associated with increased phosphorylation of ERK42/44 and PKB, but not p38 MAPK.  
 
Dexamethasone, administered intraperitoneally to rats for 10 days (3mg/kg/day) or directly added to 
the perfusate (1 μM) resulted in significant cardioprotection of hearts subjected to 20 min sustained 
global ischaemia, followed by 30 min reperfusion. This is associated with a marked upregulation of 
MKP-1 and dephosphorylation of p38 MAPK during reperfusion. 
 
These studies suggest that the phosphatases are definitely involved in the phenomenon of 
ischaemia/reperfusion and ischaemic preconditioning. However, it also become clear that extensive 
further research is required to fully elucidate which phosphatases are involved and the mechanisms 
thereof. Due to the large size of the protein phosphatase family, this may prove to be a formidable 
task and far beyond the scope of this thesis. The results also suggested that pharmacological 
targetting of phosphatases involved in phosphorylation of the reperfusion injury salvage kinase 
(RISK) pathway (e.g. ERK42/44 and PKB/Akt) or dephosphorylation of pro-apoptotic kinases, such 
as p38 MAPK, may have significant clinical potential.  
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ABSTRAK 
 
Proteïenkinases en fosfatases speel 'n belangrike rol in die fosforileringstatus van intrasellulêre 
proteïene in beide fisiologiese en patofisiologiese toestande.  In teenstelling met die groot aantal 
studies gedoen ten einde die rol van die kinases, veral die mitogeen-geaktiveerde proteïenkinases 
(MAPKs), in iskemie/herperfusie en iskemiese prekondisionering te ondersoek, is relatief min 
bekend aangaande die rol van die fosfatases in hierdie scenario.  Hoewel verskeie rolspelers in 
die seintransduksieprosesse van iskemie/herperfusie en iskemiese prekondisionering reeds 
geïdentifiseer is, is die presiese meganisme van miokardiale beskerming steeds onbekend. 
 
Vroeëre studies vanuit ons laboratorium het getoon dat die streskinase, p38 MAPK, 'n tweeledige 
rol in prekondisionering speel:  dit is 'n sneller ("trigger") van die proses, terwyl verlaagde 
aktivering tydens volgehoue iskemie en herperfusie, noodsaaklik vir beskerming is.  Ons hipotese 
is dus dat die balans tussen die aktiveringstatus van die MAPKs en induksie van fosfatases die 
oorlewing van kardiomiosiete blootgestel aan iskemiese stres, bepaal. 
 
Die doelwitte van hierdie studie was:  (1) bepaling van die aktiwiteit van miokardiale proteïen 
fosfatases (PSPs en PP1) tydens volgehoue iskemie en herperfusie van nie-geprekondisioneerde 
en iskemies-geprekondisioneerde harte;  (ii) evaluering van die belang van fosfatases in 
iskemie/herperfusie beskadiging sowel as in iskemiese prekondisionering deur van geskikte 
inhibitore gebruik te maak;  (iii) ondersoek na die rol van die fosfatase, mitogeen-geaktiveerde 
proteïen kinase fosfatase-1 (MPK-1) in iskemie/herperfusie beskadiging.  Dit is bekend dat MKP-1 
deur strestoestande opgereguleer word en p38 MAPK selektief deur defosforilasie van die 
regulatoriese Thr en Tyr residue inaktiveer word.  Die glukokortikoïed, deksametasoon, wat MKP-1 
uitdrukking stimuleer, is as agonis gebruik ten einde MKP-1 eksperimenteel op te reguleer. 
 
Die geïsoleerde, geperfuseerde werkende rothart is as eksperimentele model gebruik.  Na 
stabilisasie, is die harte aan 'n enkel- of veelvuldige siklus iskemiese prekondisioneringsprotokol 
onderwerp, gevolg deur volgehoue globale of streeksiskemie.  Nie-geprekondisioneerde harte is 
slegs aan iskemie/herperfusie onderwerp.  Harte is op verskillende tye tydens die perfusieprotokol 
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gevriesklamp vir Western blot analise van die MAPKs, PKB/Akt en MKP-1.  Infarktgrootte en 
funksionele herstel tydens herperfusie is as indikators van iskemiese beskadiging gebruik.  
Fosforilasie van MAPKs en PKB/Akt sowel as uitdrukking van MKP-1 tydens vroeë herperfusie is 
gemonitor. 
 
Die resultate toon dat aktivering van PSP en PP1 tydens volgehoue iskemie en herperfusie nie 
plaasvind nie.  Die rol van die fosfatases is verder ondersoek deur van twee inhibitore gebruik te 
maak, naamlik cantharidin (5 μM inhibeer beide PP1 en PP2A) en okadaic suur (7.5 nM inhibeer 
PP2A selektief).  Toediening van of cantharidin of okadaic suur tydens die 
prekondisioneringsprotokol, hef prekondisionering-geïnduseerde beskerming totaal op, soos 
aangetoon deur hartversaking tydens herperfusie en 'n toename in infarktgrootte, tesame met 'n 
toename in die fosforilering van p38 MAPK en PKB/Akt en defosforilering van ERK42/44.  Hierdie 
waarnemings dui op 'n rol vir PP2A as sneller in prekondisionering.  Toediening van hierdie 
inhibitore tydens vroeë herperfusie het ook die miokardium beskerm, soos aangetoon deur 'n 
verbeterde meganiese herstel van geprekondisioneerde harte, tesame met ‘n verhoogde 
fosforilering van ERK42/44 en PKB (maar nie p38 MAPK nie). 
 
Deksametasoon, intraperitoneaal toegedien, vir 10 dae (3mg/kg/dag) of direk by die perfusaat 
gevoeg (1μM), het tot 'n hoogs beduidende beskerming teen iskemiese beskadiging gelei van harte 
blootgestel aan 20 min globale iskemie en 30 min herperfusie.  Hierdie toename in funksionele 
herstel en afname in infarktgrootte het met 'n toename in MKP-1 uitdrukking en defosforilasie van 
p38 MAPK gepaard gegaan. 
 
Bogenoemde resultate dui op 'n definitiewe betrokkenheid van fosfatases in iskemie/herperfusie en 
iskemiese prekondisionering.  Dit is egter ook duidelik dat intensiewe verdere navorsing benodig 
word om die presiese rol van die fosfatases te bepaal.  Vanweë die grootte van die fosfatase 
familie, val dit egter buite die beskek van hierdie studie.  Ten slotte, die resultate toon dat 
farmakologiese manipulasie van fosfatases betrokke by die fosforileringstatus van anti-apoptotiese 
kinases soos ERK42/44 en PKB/Akt en defosforilasie van pro-apoptotiese kinases, soos p38 MAPK, 
besondere kliniese toepassings mag hê. 
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CHAPTER 1 
Protein Phosphatases 
 
1.1 General introduction
 
Protein phosphatases comprise several families of enzymes that catalyze the dephosphorylation of 
intracellular phosphoproteins, thereby reversing the action of protein kinases. Most 
phosphorylations are reversible, implying that the phosphorylation level of a protein reflects the 
balance between the activities of the involved protein phosphatases and protein kinases. Reversible 
protein phosphorylation is the basis for the regulation of many diverse cellular processes that 
include metabolism, contractility, transport, cell division, differentiation and development, learning 
and memory. About one-third of all eukaryotic proteins are controlled by phosphorylation of specific 
serine, threonine, and/or tyrosine residues (there is also evidence for histidine phosphorylation).  
The importance of phosphorylation and dephosphorylation in intracellular signalling pathways has 
long been recognized, although attention has been focussed mainly on kinases because protein 
kinases have been relatively easy to study by measuring the incorporation of radioactive phosphate 
from [γ-32P ATP] into proteins or specific peptide substrates, but characterization of protein 
phosphatases is a more difficult task. Before one can assay activity of a protein phosphatase a 
suitably purified phosphorylated substrate must be prepared. This includes the commonly-used 
model protein substrate, Myelin Basic protein (MyBP), which can be used for assay of type 1 and 
type 2 protein serine/threonine phosphatases as well as dual specificity protein phosphatases. 
The protein phosphatases that dephosphorylate protein kinases have not been well investigated. 
Future studies are required for identification of protein phosphatases and a better understanding of 
the cellular mechanisms that control the balance between protein phosphatases and protein 
kinases could lead to therapeutic strategies to limit many diseases including cardiovascular 
diseases, cancer and inflammatory diseases.  
This literature review will therefore give a brief description of the major classes of phosphatases, 
with particular emphasis on the current knowledge of and insight in their roles in myocardial 
ischaemia/reperfusion damage and the phenomenon of preconditioning.  
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1.2 Literature Review  
 
1.2.1 Protein Phosphatases
 
Protein phosphatases are classified into five independent protein families according to their 
substrate specificities, catalytic mechanisms and amino acid sequences, namely, PSPs: Ser/Thr 
phosphatases, DSPs (dual-specificity): Ser/Thr/Tyr phosphatases, PTPs: Tyr phosphatases, PHPs: 
Histidine (His) phosphatases and PTEN (phosphatase and tensin homolog deleted on chromosome 
ten): dual protein–lipid phosphatases.  
It is well established that protein phosphorylation levels can be modulated by changes in the 
activities of protein kinases (enzymes that add phosphate groups to target proteins) and protein 
phosphatases (enzymes that hydrolyze phosphate esters and amidates). About one-third of all 
eukaryotic proteins are controlled by phosphorylation of specific serine, threonine, and/or tyrosine 
residues. Eukaryotic cells express a large variety of protein kinases and phosphatases, each with 
their own substrate specificity, subcellular localization, and regulation. There are 400 protein 
serine/threonine kinases and 100 protein tyrosine kinases encoded in mammalian genome, in 
contrast to only 25 protein serine/threonine phosphatases and 100 protein tyrosine phosphatases 
(1). This has been accounted for by distinct diversification strategies during evolution (2). Because a 
single phosphatase catalytic moiety often associates with several different regulatory or targeting 
subunits, the total number of functional phosphatase holoenzymes is expected to be similar to the 
number of protein kinases when holoenzymes are considered (see reference 3). In order to 
counteract the large number of protein kinases, protein phosphatases exhibit broad substrate 
specificity and interact with numerous regulatory and targeting proteins that control the activities of 
phosphatases by changing the conformation and location of these enzymes. Kinases and 
phosphatases may even be colocalized on the same protein but at different docking sites (4, 5). 
Since the discovery of protein phosphorylation–dephosphorylation as a possible regulatory device 
in the mid-1950s, there has been a steady expansion of the field. 
In theory, one kinase and one phosphatase can operate a regulatory cycle. In practice, however, a 
multitude of cycles are intimately interrelated through overlapping substrates and, more importantly, 
through the mutual regulation of kinases and phosphatases by other kinases and phosphatases. 
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These regulatory cycles possess an enormous capacity for amplification, integration and 
processing of internal and external signals. It is probable that with the flurry of interest in genomics 
and proteomics, all of the protein kinase and phosphatase catalytic subunits or domains will soon be 
ascertained (see reference 6).  
The phosphorylation–dephosphorylation state of a protein can profoundly affect its localization and 
redistribution. Almost any protein molecule involved and almost every single step of signalling 
cascades are associated with phosphorylation and dephosphorylation processes. For example, 
reversible phosphorylation and dephosphorylation by kinases and phosphatases respectively are 
the main mechanisms whereby apoptosis is regulated by the anti-apoptotic pro-survival kinase 
phosphatidylinositol-3-OH kinase (PI3K)-Akt (7, 7A, 8) and the Raf–mitogen activated protein 
kinase (MAPK), extracellular signal-regulated kinase (Raf–MEK1/2–ERk1/2) signalling cascades (9, 
9A) ( the so-called reperfusion injury salvage kinase (RISK) pathway (10).  
Phosphatase molecules which are capable of negatively regulating the stress activated protein 
kinase (SAPK) signalling pathway include members of four distinct groups: DSP, PP2C, PP2A and 
PTP, each mediating a distinct function. Differences in substrate specificities and regulatory 
mechanisms for these phosphatases form the molecular basis for the complex regulation of SAPK 
signalling. Regulation of a single substrate by multiple protein phosphatases suggests redundancy 
(11-14).  
More insight in the regulation of protein phosphatases is required before they can be pursued as 
therapeutic targets (15). For example, studying the pathogenesis of signalling pathways often 
reveals an apoptotic component that contributes to disease progression. As the apoptotic program 
is fundamentally regulated by phosphorylation of specific regulatory proteins, influencing these 
phosphorylation processes offers the ability to modulate the life or death of cells. In particular, 
inhibitors of phosphatases could become promising candidates for therapy of many diseases.  
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1.2.1.1 Protein serine/threonine phosphatases. 
Protein serine/threonine phosphatases (PSPs) are specific for 
phosphoserine/phosphothreonine-containing proteins and were first identified in classical 
biochemical studies. These protein phosphatases are divided in two large subfamilies by distinct 
amino acid sequences and crystal structures. They are metal-ion-dependent protein phosphatase 
(PPM) and the phosphoprotein phosphatase (PPP) subfamilies (16). The PPM family comprises 
Mg2+-dependent enzymes, including protein phosphatase 2C (PP2C) and pyruvate dehydrogenase 
phosphatase. All other protein serine/threonine phosphatases belong to the PPP family, consisting 
of the subfamilies type-1 protein phosphatases (PP1), type-2 protein phosphatase A (PP2A) 
(including PP4 also known as PPX and PP6, a functional homologue of budding yeast Sit4), PP2B 
(also known as calcineurin), PP5 and PP7, which all have a structurally related core and a similar 
catalytic mechanism (17-19).  
PP1 (35–38 kDa) is one of the most conserved eukaryotic proteins. This is nicely illustrated by the 
early branching eukaryote Giardia lamblia, which expresses an isoform of PP1 that is 72% identical 
to the mammalian PP1 isoforms (2). Also, the phenotypes associated with mutations of PP1 in fungi 
could be (partially) complemented by expression of mammalian PP1 (20, 21), indicating that PP1 is 
also functionally conserved. Mammals have three PP1 genes, encoding the isoforms PP1α, PP1γ, 
and PP1β/δ.PP1 may also regulate glycogen metabolism and the activation of glycogen synthase 
in vivo (22-24). PP1 is inhibited by heat-stable inhibitor proteins and preferentially dephosphorylate 
the β-subunit of phosphorylase kinase. In contrast, PP2 is insensitive to these inhibitors and 
preferentially dephosphorylate the α-subunit of phosphorylase kinase. PP1 is also likely to function 
as a phosphorylase phosphatase in vivo, since alterations in the expression levels of PP1 or of 
specific G subunits resulted in corresponding changes in the activity of phosphorylase (25, 26).  
PP1 promotes the dephosphorylation of phospho-CREB and attenuate CREB signalling (27-29), 
but the involved targetting subunit is unknown. Interestingly, it was recently reported that the histone 
deacetylase HDAC1 is part of a CREB-associated complex that also includes PP1 (30). 
PP2A has been found to colocalize at the mitochondrial membrane with Bcl-2 and protects cells by 
opposing ERK-mediated Bcl-2 phosphorylation (31). PP2A is not only targeted to mitochondria by 
splice variants of its regulatory subunit (32), but also is sensitive to redox regulation (33). 
Four phosphorylation sites on BAD have been identified, Ser112 (34), Ser136 (34), Ser155 (35,36) 
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and Ser170 (37). At least PP1 (38), PP2A (39) and PP2B (40) are responsible for the 
dephosphorylation of BAD. The mechanisms of the function of the various phosphorylation sites, 
however, are not the same for all positions. Phosphorylation of Ser112 and Ser136 creates binding 
sites for the interaction of BAD with 14-3-3 proteins (34), whereas phosphorylation of Ser155 
triggers dissociation of BAD from Bcl-XL (36). 
Activation of caspase-3 directly causes cleavage of the regulatory Aα subunit of PP2A (41). This in 
turn increases PP2A activity, thus affecting the phosphorylation state of a cell dramatically. PP2A 
may function in the regulation of the mammalian MAPK pathway (42): this phosphatase regulate 
Raf1-MEK1/2-ERK1/2 signalling at multiple steps in this pathway (43), so inhibition of this PP2A 
would allow for the continual activation of both these kinases. It has been shown that the action of 
PP2A regulates ERK phosphorylation (44) and it appears that ERK is a downstream target of PP2A 
activity (45). The inhibition of ERKs by a cholesterol-regulated PP2A/HePTP complex has also been 
reported in the membrane (46). Phosphorylation of p38 MAPK also can increase the activity of 
PP2A upon stimulation with stress stimuli (47-49). Activation of p38 MAPK by adenosine A1 
receptors also induces PP2A activation and translocation to the particulate fraction in 
cardiomyocytes, leading to inhibition of ERKs (49). The p38 MAPKα isoform mediates 
dephosphorylation and inhibition of PKB/Akt activity by inducing the targeting of the PP2A 
holoenzyme to caveolae through interaction with caveolin-1, which leads to survival attenuation 
upon cell adhesion (for review see 50, 51). However, regulation of PP2A by integrins can be 
mediated by p38 MAPK-independent mechanisms (52). 
At least six distinct PP2C gene products (2Cα, 2Cβ, 2Cγ, 2Cδ, Wip1 and 
Ca2+/calmodulin-dependent protein kinase phosphatase) operate in mammalian cells (53-55). 
PP2Cα, PP2Cβ and Wip1 in mammalian cells have been identified to be involved in the negative 
regulation of SAPK cascades (56, 57). In addition, PP2Cα and PP2Cβ may regulate cell cycle 
progression (58). 
The immunosuppressant drug cyclosporine, which made organ transplantation possible, was the 
first drug discovered to exert its effect by inhibiting a protein phosphatase, although it was in use 
clinically before the mechanism of action was elucidated in 1990. Cyclosporine, in association with 
its cellular binding protein cyclophilin, is a potent and specific inhibitor of the 
Ca2+/calmodulin-dependent protein phosphatase PP2B. Inhibition of PP2B prevents 
dephosphorylation of an isoform of the nuclear factor of activated T-cells (NFAT). As a result, this 
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transcription factor cannot enter the nucleus, and production of interleukin-2 is suppressed and 
T-cell proliferation reduced (59). 
1.2.1.2 Dual specificity phosphatases
Dual specificity phosphatases (DSPs) dephosphorylate protein substrates on tyrosine, serine and 
threonine residues. DSP genes share two unique structural features; they contain a common active 
site sequence motif and two N-terminal CH2 domains, homologous to the cell cycle regulator Cdc25 
(60). 
Mitogen-activated protein kinase (MAPK) phosphatases (MKPs) are a subfamily of the DSPs which 
can remove phosphates from both the threonyl and tyrosyl residues in the MAPK activation motifs. 
Although the contribution of the MAPKs to cell growth and cell death has been examined 
extensively, much less is known about whether the MKPs play an essential role in the regulation of 
these processes. It is possible that MKPs may modulate the activity of the MAPKs response to a 
stimulus (14). Since both the magnitude and duration of MAPK activity dictate the outcome of 
numerous physiological responses, it is essential to understand the contribution of MKPs to MAPK 
regulation. MKPs have been implicated in the regulation of cell survival, proliferation, apoptosis, 
differentiation, and metabolism using overexpression approaches (14, 61). 
The MKPs exhibit different specificities towards the various MAPKs (14, 61) and are critical 
negative regulators of MAPK-mediated signalling in a variety of biological processes (14, 62). 
Activation of MAPKs causes activation of dual specificity phosphatases, which in turn  
dephosphorylate the MAPKs and which are thus responsible for the temporal limitations in MAPK 
signalling.  
To date, 11 genes encoding members of the classical MKP family have been isolated and 
characterized from the mammalian genome. They all share some common features, including an 
extended active-site motif with significant sequence similarity to the corresponding region of the 
VH-1 protein tyrosine phosphatase that was isolated from vaccinia virus (63). On the basis of 
structures predicted from genomic sequence, the MKPs can readily be divided into three subgroups 
in mammalian cells, namely, subgroup I: MKP-1, MKP-2, PAC-1 and hVH3; subgroup II: MKP-3, 
MKP-4, MKP-5 and MKP-10 and subgroup III: M3/6 (hVH5) and MKP-7. Their subcellular locations 
differ: some are expressed exclusively in the nucleus, for example, MKP-1, MKP-2, PAC-1 and 
hVH3 (64-66), some (MKP-3, MKP-7 and MKP-10) are predominantly expressed in the cytoplasm 
(89, 91), whereas others (M3/6, MKP-4 and MKP-5) show both cytoplasmic and nuclear 
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localizations (67-69).  
MKP-1 (hVH-1, Erp, 3CH134, CL100) mRNA is ubiquitously expressed in various tissues, with the 
protein product localized preferentially to the cell nucleus (70). A plethora of reports have implicated 
MKP-1 in the regulation of a variety of physiological processes such as gene expression, cell 
growth, apoptosis, and immune responsiveness (14, 61). Although many studies demonstrate a role 
for MKP-1 in these biological pathways, a complete appreciation of whether MKP-1 is an essential 
physiological regulator has remained unclear. 
In addition to oxidative stress and heat shock (71), MKP-1 is induced by various stimuli such as, 
osmotic shock, anisomycin, growth factors, UV light, 12-O-tetradecanoylphorbol 13-acetate (TPA), 
Ca2+ ionophores and lipopolysaccharide (70, 72, 73). In Rat1 fibroblasts, MKP-1 is induced by 
Ca2+ signalling (74), independently of MAPK activation (74, 75). 
MKP-1 promotes cell survival by attenuating stress-responsive MAPK-mediated apoptosis. 
Overexpression of MKP-1 attenuates the activation of genes whose transcription is dependent upon 
MAPK activity. MKP-1 was identified as a critical negative regulator of the cAMP-mediated p38 
MAPK pathway. MKP-1 preferentially dephosphorylates and inactivates p38 MAPK and JNK in the 
nucleus and to a lesser extent the growth factor-responsive MAPK extracellular-regulated kinases 
(ERKs) with a rank order of p38 MAPK > JNK > ERK (72, 76-78). The stability of MKP-1 is regulated 
by ERK-mediated phosphorylation of two C-terminal serine residues (79). MKP-1 binds to 
C-terminal region of p38 MAPK, that results in its activation (70). The details of the regulatory 
mechanism depend on the cell lineage. In vascular smooth muscle cells, mesangial cells and U937 
cells, the activation of either ERK, JNK or p38 MAPK induces MKP-1; in NIH3T3 cells, the activation 
of JNK but not ERK up-regulates MKP-1 expression (72, 73, 77, 80). In addition, activation of p38 
MAPK but not ERK or JNK enhances MKP-1 induction in H4IIE hepatoma cells. 
Ca2+/calmodulin-activated protein phosphatase (PP2B) participates in the induction of MKP-1 in 
cardiac myocytes (81). 
MKP-2 (hVH2), a 42.6-kDa nuclear DSP, is widely expressed in various tissues (82) and induced by 
the nerve growth factor, TPA and hepatocyte growth factor in PC12 cells, peripheral blood T cells 
and MDCK cells, respectively (76, 82, 83). PAC-1, a DSP of 32 kDa, is found to be expressed in 
hematopoietic cells (66) and in hippocampus neurons following forebrain ischemia or kainic 
acid-induced seizure (84, 85, 86). Activation of ERK induces the enhanced expression of PAC-1 
which then inactivates ERK in T cells (87). The dual specificity phosphatase VHR (hVH3) is a 
Stellenbosch University  http://scholar.sun.ac.za
 8
low-molecular-weight DSP which lacks the amino-terminal domain (65, 86, 88). The amino-terminal 
noncatalytic domain of Pyst1 mediates the binding of ERK42 and loss of this domain abrogates 
substrate selectivity in vivo (89-92). PAC-1 and Pyst1 (MKP-3) dephosphorylate both ERK and p38 
MAPK but not JNK (60, 76, 86, 89). MKP-4 is specificity for ERK over JNK or p38 MAPK (67). 
Expression of MKP-4 mRNA is highly restricted to substrate binding (67, 93, 94). VHR and MKP-10 
have been shown to inactivate ERK in cells (65, 86, 88, 89, 91, 95). MKP-5, MKP-7 and M3/6 
preferentially dephosphorylate both JNK and p38 MAPK, but not ERK (68, 69, 89, 60, 96, 97). It has 
been found that the phosphorylation of M3/6 does not regulate its half life (98). An internal motif, 
XILPXL(Y/F)LG, homologous to the SAPK binding site of c-Jun (delta domain), is important for M3/6 
activity (98,99). MKP-2 and MKP-6 are highly specific for ERK and JNK, but not for p38 MAPK (76, 
100). MKP-6 expression is up-regulated by CD28 costimulation of T cells. Binding of the expressed 
MKP-6 to CD28 is required for the feed back regulation of ERK and JNK by MKP-6 (100). 
 
1.2.1.3 Protein tyrosine phosphatases
It is well-established that protein-tyrosine phosphorylation is an important modulator of 
posttranslational modification affecting protein–protein interactions and enzymatic activities. Protein 
tyrosine phosphatases (PTPs) are specific for these phosphotyrosine-containing proteins and 
composed of transmembrane (receptor-like) and cytosolic (non-receptor) subfamilies. Currently, 
more PTPs have been characterized (101-103) , although the PC12 cell PTPs were not identified 
molecularly (104). 
Receptor protein-tyrosine phosphatases (RPTPs) belong to the family of 
single-membrane-spanning PTPs, which act together with the antagonistically acting 
protein-tyrosine kinases (PTKs), to regulate the protein phosphotyrosine levels in cells (105). Thus, 
the cellular equilibrium of protein tyrosine phosphorylation is achieved through the actions of PTKs 
and PTPs. Disrupting the equilibrium of cellular tyrosine phosphorylation can cause a plethora of 
human diseases (see reference 106) and demonstrates the importance of tightly controlling the 
activities of both PTKs and PTPs. The PTKs were discovered almost a decade before PTPs, so the 
knowledge of the molecular actions of PTKs in normal cell signalling and human disease is much 
more than that of the PTPs. Recent studies demonstrated that RPTPs, like RPTKs, are regulated by 
dimerization. For example, it has been shown that oxidative stress regulates RPTP dimer formation 
(105). These phosphatases not only counterbalance the effects of receptor and cytosolic PTKs but 
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also transmit information through the plasma membrane. PTPs contain a highly conserved cysteine 
residue that is essential for the catalytic reaction. In contrast with the DSPs, the identification of 
substrates for the non-transmembrane tyrosine-specific PTPs has been much more problematic, 
now that all of the genes that comprise the PTP superfamily have been identified (107). The ability 
of PTP family members to differentiate between individual substrates can be attributed to the 
inherent specificity within the PTP catalytic domain. The catalytic domains of classical PTPs contain 
approx 280 residues and comprise 22 invariant and 42 highly conserved residues that fall within ten 
consensus motifs (108,109).  A role for PTPases in regulating MAPK first came from genetic and 
biochemical studies of the osmoregulatory MAPK pathways in yeasts (110,111). PTPs were 
observed to inactivate ERKs (104,112). The Hog1p osmoregulatory MAPK in budding yeast is 
regulated by two tyrosine specific phosphatases encoded by PTP2 and PTP3 (110,111). 
Three related PTP gene family members have been identified, namely, STEP (striatal enriched 
phosphatase), PTP-SL (STEP-like phosphatase, also known as PCPTP1) and HePTP (same as 
LC-PTP). STEP and PTP-SL are two homologous neuronal PTPs existing in both transmembrane 
and cytosolic forms that bind tightly as well as dephosphorylate and inactivate ERKs (112). HePTP 
is an additional cytosolic PTP present in lymphoid tissue also reported recently to bind and 
inactivate the MAPKs (12, 13, 113). PTP-SL, STEP, and HePTP appear to act as functional 
homologues of the tyrosine-specific PTPs Ptp2 and Ptp3 as well as Pyp1 and Pyp2, identified 
genetically as down-regulators of the MAPKs in budding and fission yeast, respectively (114, 115).  
1.2.1.4 Protein histidine phosphatases
A unique protein phosphatase responsible for histidine dephosphorylation has been identified 
recently, named protein histidine phosphatases (PHPs) (see reference 6, 116). PHPs are unlike any 
of the known Ser/Thr or Tyr phosphatases. In contrast to the relatively well studied processes of 
Ser/Thr and Tyr phosphorylation, PHPs phosphorylation in eukaryotes is an emerging field.  
There are important examples of phosphohistidine in mammalian proteins (e.g. G-proteins, 
P-selectin and annexin). Although corresponding mammalian His kinases still remain an enigma, a 
PHP has been discovered in vertebrates (see reference 6). Its primary structure and insensitivity to 
known inhibitors indicate that this is a novel protein.  
Interestingly, PHP has been shown to be present in animals ranging from humans to nematodes but 
absent in bacteria. However, it became obvious that the role of His phosphorylation and 
dephosphorylation in mammalian cells is only just beginning to be explored (see reference 6). 
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1.2.1.5 Phosphatase and tensin homolog deleted on chromosome ten
Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a dual protein–lipid 
phosphatase which was discovered relatively recently (117, 118). PTEN dephosphorylates the 
second-messenger PtdIns(3,4,5)P3 (PIP3) to the precursor PtdIns(4,5)P2 (PIP2) and negatively 
regulates the PI3K/Akt pathway (119, 120). 
PTEN also is called MMAC1 (mutated in multiple advanced cancers) or TEP-1 (TGF- regulated and 
epithelial cell-enriched phosphatase) and is present ubiquitously in cells and its activity is reflected 
by its cellular level, which can be modulated by transcription.  
PTEN plays a significant role in regulating the balance between survival and death in many cell 
types, including cardiomyocytes. One of the mechanisms of its inactivation is via phosphorylation. It 
has been suggested that its activity can be upregulated by increased synthesis and downregulated 
by phosphorylation, oxidation and proteasomal degradation (121-123). Although PTEN 
downregulation may seem potentially harmful because it could promote unwanted growth and 
malignancies, the mechanisms through which its activity are regulated are complex and not yet 
elucidated completely (see reference 124). 
It is also known that homozygous PTEN knockout mice are not viable whereas the heterozygous 
animals develop numerous tumors. In addition, in humans, many tumor types are characterized by 
deficient PTEN expression (125). 
It has been demonstrated that PTEN can be inhibited by vanadium compounds (126, 127). Based 
on the homology of the active site between PTEN and protein tyrosine phosphatases (PTPs), it has 
been shown that PTP inhibitors such as bisperoxovanadium molecules can also inhibit PTEN. 
Sodium orthovanadate was shown to protect against cerebral ischaemia by increasing the tyrosine 
phosphorylation of PTEN (127). It was also documented that zinc ions downregulate PTEN 
expression in airway epithelial cells in a dose- and time-dependent fashion, via increased 
proteasome-mediated degradation and reduced PTEN messenger RNA expression (128). 
PTEN may play a significant role in pathological conditions associated with the ischaemic heart 
disease (129). PTEN inhibition could ultimately prove to be significant in improving myocardial 
survival following ischaemia/reperfusion injury. A reversible inhibition of PTEN may be enough to 
upregulate the prosurvival PI3K/Akt pathway to reduce the cell death associated with such injury, 
without the negative hypertrophic consequences (see reference 130). 
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1.2.2 Introduction to preconditioning
 
1.2.2.1 Ischaemic preconditioning: a brief description
Myocardial ischaemic preconditioning is a phenomenon by whereby exposure to one or more short 
episodes of ischaemia/reperfusion increases the ability of the heart to tolerate a subsequent 
prolonged period of ischaemic injury (131-134). This phenomenon was first described by Murry et al 
(131) in the canine infarct model. In view of its possible clinical application, this finding evoked 
enormous interest from clinicians and researchers and several reviews on the topic have been 
published (for reviews see 135-137). In view of these, only a brief overview of the phenomenon will 
be given below.  
Ischemic preconditioning represents a powerful procedure to protect ischaemic-reperfused 
myocardium in all animal species investigated thus far: dogs (131), rabbits (138-140), rats (141-144), 
pigs (145,146) as well as in human isolated myocytes (147), human muscle tissue (148). 
Furthermore, and most promising, it has also been reported to occur in in-vivo human hearts 
(149-151).  
Preconditioning induced cardioprotection is reduced in the aged as compared to the young adult rat 
heart (144, 152), also in adult and elderly human patients with myocardial infarction (152). 
Not all time combinations and durations of ischaemia and reperfusion will trigger the preconditioning 
phenomenon and afford myocardial protection. In a preconditioning protocol, ischaemic episodes 
as short as 3–5 min followed by a minimal 5 min of reperfusion protects the myocardium (131), but a 
brief 1–2 min of preconditioning ischaemia followed by subsequent reperfusion has no protective 
effect (153-155).  A single episode of ischaemia is essential to induce preconditioning (139, 156), 
but repetitive episodes of brief ischaemia are also effective (157, 158), and may enhance the 
cardioprotective effects. The duration of intermittent reperfusion is also meaningful. Typically, a 
5-min period of ischaemia followed by up to 60 min of reperfusion prior to the sustained ischaemic 
insult results in salvage. One to four hours later protection is no longer evident (153, 159). However, 
if the time between the initial stimulus and sustained ischaemia is prolonged to 24–96 h, the 
protective effect may again be seen (157, 160). 
The protection elicited by ischaemic preconditioning therefore appears in two separate phases or 
‘windows’. The term ‘classic’ or ‘early preconditioning’ refers to the effect of a brief bout(s) of 
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ischaemia (for example 5 min) followed shortly thereafter by a second insult which results in 
significant protection over 2–3 h following a preconditioning stimulus (131, 161, 162). If the time 
between the initial stimulus and sustained ischaemia is prolonged to 24–96 h, a second, but less 
significant, phase of cardioprotection was observed. This was initially labeled ‘second window of 
protection’, but is now termed ‘delayed’ or ‘late preconditioning’. 
Ischaemic preconditioning protects the myocardium against various deleterious effects of ischaemia 
such as slowing energy metabolism during the early stages of ischaemia (163), reducing the 
incidence and severity of reperfusion-induced arrhythmias (164-167), improving post-ischaemic 
recovery of function (168), preventing endothelial cell dysfunction (164-166), increasing the 
post-ischaemic developed tension in isolated atrial trabeculae muscles following simulated 
ischaemia (147, 148) and improving the resistance of isolated myocytes to hypoxic injury (169). It is 
also known as the most effective intervention to reduce infarct size during ischaemia/reperfusion 
and indicates that the heart has at its disposal a powerful endogenous protective mechanism, 
elicited by exposure to short periods of ischaemic stress. Amongst others, ischaemic 
preconditioning mediates protection through the recruitment of downstream antiapoptotic pathways 
of cellular survival (10, 170). These include the phosphorylation and inactivation of proapoptotic 
proteins such as BAD (171), Bax (172, 173), Bim (173) and caspases (174, 175), and the 
phosphorylation and activation of endothelial nitric oxide synthase (eNOS) (176), p70S6 kinase 
(177, 178), and protein kinase C (PKC) (179). It also attenuates release of cytochrome C from 
mitochondria (180, 181) and reduces neutrophil accumulation (182, 183). 
 
1.2.2.2 Signalling in preconditioning. 
It has become clear that numerous triggers and mediators can elicit this protective mechanism, and 
a major objective in recent years has been the identification of these triggers, mediators and also 
end effectors involved in the cardioprotection elicited by ischaemic preconditioning. A number of 
triggers are released during the short episodes of ischemia/reperfusion. Receptor dependent 
triggers are adenosine (138, 184, 185), opioids (186-188), bradykinin (189, 190), prostaglandins, 
norepinephrine, angiotensin and endothelin (191-194). This indicates that virtually all guanylyl 
inhibitory (Gi) protein coupled receptors in the heart can trigger the preconditioned phenotype. 
Receptor independent triggers are nitric oxide (NO) (193-195), reactive oxygen species (ROS) (196, 
197) and calcium (198-201). ROS, in particular, which appear to be important in the triggering 
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process, are formed during the reperfusion phase of the preconditioning protocol (see reference 
135). 
The receptor dependent triggers activate very divergent pathways, although several converge again 
at PKC (for a review see 137, 202). Another important role player in triggering preconditioning is 
PI3-kinase activation, which occurs upstream of PKC. PI3-kinase activation in turn results in rapid 
phosphorylation, and hence activation of PKB/Akt (203). 
PKB/Akt is known to stimulate nitric oxide synthase (NOS) to produce NO, which in turn, activates 
guanylyl cyclase, resulting in cGMP formation and PKG activation (204) during the triggering 
process. In 2005, Costa and coworkers (205) showed that PKG resulted in opening of the 
mitochondrial K+ATP channels, which has been proposed to be an end-effector of preconditioning. 
However, opening of these channels also appears to participate in the triggering process, since this 
is thought to lead to ROS production, resulting in PKC activation (136, 137, 206). 
In 2004, a significant paradigm shift occurred: while it was previously generally accepted that 
protection occurred during the ischaemic period and that reperfusion allowed cells to recover from 
the damage caused by ischaemia, Hausenloy and coworkers (207) demonstrated that protection 
actually occurs during the early reperfusion period following ischaemia. Ischaemic preconditioning 
causes activation of PI3-K/Akt as well as the MEK1/2-ERK1/2 cascades during this stage. This 
appears to be very important, since pharmacological inhibition of these events abrogates 
cardioprotection. 
The next step was to determine how the survival kinases are activated during reperfusion. 
Solenkova and coworkers (208) showed that blockade of the adenosine receptor during the first few 
min of reperfusion prevented activation of PKB/Akt as well as the anti-infarct effect of ischaemic 
preconditioning. Further studies by the same group suggested involvement of the adenosine A2β 
receptor in particular. 
The survival kinases, although important, are not the end-effectors of preconditioning: they are 
merely signalling molecules to transport the signal. It has also been shown that phosphorylation of 
glycogen synthase kinase 3β (GSK3β) (209) ( and inactivation of this particular kinase) by several 
kinases occurs in ischaemic preconditioning, preventing formation of the mitochondrial permeability 
transition pore (MPTP) (210). Hausenloy and his coworkers recently reported that the final step of 
the signal transduction pathway is inhibition of MPTP (211, 212). This pore is thought to be formed 
by alignment of the adenine nucleotide translocator on the inner mitochondrial membrane and the 
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voltage dependent anion channel on the outer membrane, with the small protein cyclophilin D 
playing an important role (212).  
It can be concluded from the above that the focus thus far has been mainly on the large number of 
kinases involved in the process of preconditioning, evoking phosphorylation reactions which, in 
most cases, lead to activation of that particular kinase. However, very little indeed is known about 
the role of the phosphatases in this scenario.  
1.2.3 Protein phosphatases in the heart
1.2.3.1 Effects on contractility and relaxation
It is well-established that phosphatases and kinases are important role players in the regulation of 
contractility and relaxation of the heart. Increases in protein phosphorylation and enhanced cardiac 
function are reversed by protein dephosphorylation in a highly regulated manner. 
Phosphatase expression in the heart is age-dependent and regionally different, with neonates 
having an about two-fold higher activity than adults (213), with the ventricles having a higher activity 
than the atria (214, 215). Phosphatase activity has been found to be increased in human heart 
failure (216). The activity of PP1 was found to be increased by 32% in ventricular membranes from 
infarcted hearts compared to control hearts (215). 
Chronic beta-adrenergic stimulation has been found to enhance phosphatase (PP1 and PP2A) 
activity in the heart (217). The anti-adrenergic actions of adenosine can be attributed to PP2A 
activation. A recent study by Liu and Hofmann (49) showed that adenosine A1-receptor mediated 
PP2A activation occurs via a pertussis toxin-sensitive Gi protein-guanylyl cyclase-p38 MAPK 
pathway. This proposed novel pathway may play a role in acute modulation of cardiac function. 
Recently, particular attention has been focused on phospholamban (PLB) which plays an important 
role in the activation of the SR Ca2+ pump (SERCA). Phosphorylation of PLB occurs via PKA or a 
Ca2+ calmodulin dependent protein kinase while it is dephosphorylated mainly by PP1 and PP2A 
(218). It has been shown that dephosphorylation of phospholamban reduces the activity of the 
associated SERCA pump (218), causing a reduced uptake of Ca2+. PKA, on the other hand, 
reduces the antagonistic downregulation of Ca2+ by PP1.  
The downregulated beta-adrenergic signaling in human heart failure correlated with decreased 
cAMP levels and hypophosphorylation of inhibitor-1 and phospholamban (219, 220). PP1 is 
regulated by two heat and acid stable proteins, inhibitors1 (I-1) and 2 (I-2). I-1 becomes active upon 
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phosphorylation on threonine 35 by PKA. This results in inhibition of PP1 and therefore enhanced 
PKA-mediated protein phosphorylation. Overexpression of PP1 led to a hypophosphorylation of 
phospholamban Ser-16, and the increased PP1 activity in inhibitor-1 null mice correlated with a 
hypophosphorylation of both Ser-16 and Thr-17. Not surprisingly, inhibitor-1 knock-out mice 
displayed a mildly depressed cardiac function (219). Moreover, a cardiomyocyte-restricted 
overexpression of PP1 was even associated with a severely impaired cardiac function, dilated 
cardiomyopathy, and increased mortality from heart failure (219). On the other hand, inhibition of 
PP1 and therefore enhanced PKA-mediated protein phosphorylation lead to amplification of the 
beta-response. Thus beta-adrenergic stimulation of the heart leads not only to PLB phosphorylation, 
but also inhibits PP1 activity which occurs in an indirect way (221). 
In both excitable and nonexcitable cells, two distantly related types of tetrameric receptors, the 
ryanodine receptors (RyRs) and the inositol 1,4,5-trisphosphate receptors (IP3Rs), function as Ca2+ 
release channels of the sarcoplasmic reticulum (222). Unexpectedly, RyR2 channels in failing 
hearts were found to be hyperphosphorylated, and the levels of attached PP1 and PP2A were 
decreased (223). RyR-associated PP1 and/or PP2A are thought to counteract PKA-mediated 
protein phosphorylation. PKA increases RyR2-dependent Ca2+ release during contraction and 
indirectly promotes SERCA2a-mediated Ca2+ uptake during relaxation via the phosphorylation of 
phospholamban. Indeed, PKA-dependent phosphorylation of the related protein Neurabin-I has 
been shown to dissociate PP1 (224, 225). Recent studies (226) also demonstrated that the Na+ 
channel represents a target molecule for PP1. 
PP1 also plays an important role in the dephosphorylation of the regulatory light chains associated 
with myosin heavy chains in muscle (for a review see 227). The organization and dynamics of the 
actin cytoskeleton is tightly controlled by reversible protein phosphorylation, and this regulation 
clearly involves PP1 (228). All known myosin phosphatases consist of PP1 (229-231) and has both 
a large and a small myosin phosphatase targetting (Mypt) subunit (229, 232, 233). The large Mypt 
targets PP1 to myosin and determines the substrate specificity of the phosphatase (234). The 
function of the small Mypt remains unclear, but it is known to interact directly with myosin and the 
large Mypt (235). 
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1.2.3.2 Effects of ischaemia/reperfusion on phosphatase activity
The activation status of the myocardial phosphatases during ischaemia/reperfusion obviously 
should be important in determining the phosphorylation of kinases. PP1 and PP2A are present in 
the heart, with the amount of PP2A being ～3 times higher than that of PP1 (236). PP2A activity is 
also present in isolated rat cardiomyocytes (237). 
Most of these studies used phosphatase inhibitors to demonstrate involvement of these enzymes. 
However, interpretation of the results is complicated by the lack of specificity of many of these 
inhibitors. Armstrong, Ganote and coworkers (238) showed that protein phosphatase inhibitors 
calyculin A and fostriecin protected isolated rabbit cardiomycytes from ischaemic damage, 
suggesting a role for PP2A activation in ischaemic damage. As expected, incubation with calyculin A 
induced high levels of p38 MAPK activity. Weinbrenner and coworkers (239) also reported that 
fostriecin, a potent inhibitor of PP2A, protects against ischaemia in rabbits. 
PP2A regulates the phosphorylation of MAPK cascades (43, 44). A cholesterol-regulated 
PP2A/HePTP complex was also reported to inhibit ERK activity in the membrane (46). PP2A may 
function in the regulation of the mammalian SAPK pathway (42). Phosphorylation of p38 MAPK also 
can increase the activity of PP2A upon stimulation with stress stimuli (47-49). As stated previously, 
activation of p38 MAPK by adenosine A1 receptors can also induce PP2A activation and translocate 
to the particulate fraction in cardiomyocytes, leading to inhibition of ERKs (49). It has also been 
reported that the isoenzyme p38 MAPKα mediates dephosphorylation and inhibition of PKB/Akt 
activity by inducing the targeting of the PP2A holoenzyme to caveolae through interaction with 
caveolin-1. This leads to survival attenuation upon cell adhesion (for reviews see 50, 51). However, 
regulation of PP2A by integrins can be mediated by p38 MAPK-independent mechanisms (52). 
It should be pointed out that the effects of phosphatase inhibitors on kinase activity during 
ischaemia differ between the species. The p38 MAPK activation during sustained ischaemia in 
rabbits was suggested to be cardioprotective (239A), which is in agreement with the effects 
observed using phosphatase inhibitors (238-240). However, in contrast to the results obtained in 
rabbit cardiomyocytes, Mackay and Mochley-Rosen (241) showed in rat neonatal cardiomyocytes 
that the tyrosine phosphatase inhibitor, vanadate, extended the strength and length of p38 MAPK 
activation during ischaemia, resulting in a higher susceptibility to cell death. They concluded that a 
tyrosine phosphatase is inactivated during ischaemia resulting in prolonged p38 MAPK activation 
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and cell death. 
Thus inhibition of dephosphorylation rates or stimulation of kinase activity may protect or damage 
cells by maintaining protein phosphorylation during ischaemia, depending on the animal species. 
Clearly, in view of these controversial results, the role of phosphatases in ischaemia/reperfusion 
warrants further investigation. 
 
1.2.3.3 Preconditioning and phosphatases
As in the case of ischaemia/reperfusion, little information is available regarding the role of protein 
phosphatases in preconditioning-induced cardioprotection. However, in view of the marked changes 
in the activation state of several kinases during an ischaemic preconditioning protocol (242, 243), it 
is to be expected that the protein phosphatases also play an important role in this protocol. As far as 
we know, measurement of protein phosphatase activity per se during sustained ischaemia of 
preconditioned and non-preconditioned hearts or isolated cardiomyocytes was determined in one 
study only (239)  
A number of reports showed that inhibitors of protein phosphatases (PP) imitated ischaemic 
preconditioning in some experimental models (238, 239, 240). For example, the aging-induced 
increase in the dephosphorylation of proteins can be reversed by the inhibition of endogenous 
protein phosphatases associated with preconditioning signalling, while enhancing the 
phosphorylation state of cellular proteins by the inhibition of protein phosphatase activity in the 
young adult cardiac preparations mimics preconditioning and limits cell death occurring in response 
to ischaemia (238, 239, 244, 245). Armstrong and Ganote (240) reported that phosphatase 
inhibitors, such as fostriecin, could mimic the cardioprotective effects of preconditioning. Additional 
evidence for the possible involvement of PP2A in triggering preconditioning, is the finding that 
adenosine, a well-established trigger of preconditioning, causes PP2A activation in ventricular 
myocytes via a pertussis toxin-sensitive Gi protein-guanylyl cyclase-p38 MAPK pathway (49). 
Indications are that elevations in tissue cAMP and cGMP, which occur during short episodes of 
ischaemia (5 min, as in ischaemic preconditioning), leading to activation of p38 MAPK (242, 246) 
may in turn cause activation of the phosphatase. This is in agreement with the finding that p38 
MAPK activation may act as a trigger of ischaemic preconditioning (242) and could explain the 
transient nature of p38 MAPK activation during a multi-cycle preconditioning phase. Stimulation of 
MAPKs activities by phosphatase inhibitors such as okadaic acid exerted cardioprotective effects 
Stellenbosch University  http://scholar.sun.ac.za
 18
associated with stimulation of JNK and p38 MAPK (244, 247) and mimicked the anti-infarct effects 
of preconditioning in several animal models (248,249). These results, however, are in contrast to 
those reported by Weinbrenner et al (239) who could not demonstrate that inhibition of PP1 or PP2A 
was involved in the mechanism of preconditioning. 
Ladilov and coworkers (see reference 250) recently suggested that PP1 was a mediator of hypoxic 
preconditioning (HP) in isolated heart since the inhibitor cantharidin (used at 20 μM which inhibits 
both PP1 and PP2A) abolishes hypoxic preconditioning, while okadaic acid (at 5 nM, which inhibits 
PP2A only) enhanced protection. Armstrong et al also reported that PP1 activation represents a 
mediator of HP protection in a rat model, whereas PP2A activation has the opposite effect (238, 
240). They demonstrated that hypoxic preconditioning led to a significant reduction of Ca2+ overload 
in anoxic myocytes and suggested that this was the cellular basis of hypoxic preconditioning. Ca2+ 
accumulation in ischaemia, in turn is linked to intracellular Na+ overload (251). It was recently 
demonstrated that the Na+ channel represents a target molecule for PP1 (226) and it was 
suggested that Na+ overload in hypoxic cardiomyocytes subjected to phosphatase inhibition are 
due to changes in the phosphorylation of Na+ channels (see reference 250). These results 
suggested that HP provides protection of isolated hearts and cardiomyocytes against ischaemic 
injury by a mechanism endogenously antagonized by PP2A activation and supported by activation 
of PP1.  
It is noteworthy that the phosphatase-dependent HP effect is found in the same experimental model 
(isolated cardiomyocytes from the adult rat) as the PKC-dependent mechanism of protection(252). 
It also was reported in some biological models that PP2A inhibition in ischaemic preconditioning can 
provide myocardial protection against ischaemia independent of PKC activation (158, 192, 253, 
254). 
An increase in tyrosine residue phosphorylation via increased tyrosine kinase activity has been 
implicated in the signal transduction pathway of ischemic preconditioning (255, 256). Vanadate has 
been shown to enhance tyrosine residue phosphorylation by inhibition of tyrosine phosphatase (257, 
258). Liem and coworkers (see reference 259) have shown that administration of vanadate to rats 
caused a significant reduction in infarct size, when administered before coronary artery ligation, 
suggesting that the tyrosine phosphorylation state is an important determinant of 
ischaemia/reperfusion damage. These workers also demonstrated that the cardioprotective actions 
of vanadate could be abolished by the K+ATP channel blocker, glibenclamide, suggesting that 
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opening of the K+ATP channel is involved in the actions of vanadate. Thus phosphatase inhibition 
might play an important role in preconditioning. These findings however are in direct contrast to 
those reported by Mackay and Mochly-Rosen (241) who showed that vanadate caused a higher 
susceptibility to cell death. It is obvious that these contradictory observations need to be further 
evaluated. 
It is clear that our knowledge regarding the phosphatases in the heart, particularly during 
ischaemia/reperfusion and preconditioning-induced cardioprotection, is incomplete. The 
phosphatases may be of enormous significance in this regard, but our insight is severely hampered 
by the lack of basic information regarding the behaviour of these enzymes in the heart. In view of 
the putative significance of kinases in cardiac pathology, pharmacological manipulation of the 
phosphatases may become a significant new therapeutic target. In order to do so, our knowledge 
regarding the roles of the phosphatases in ischaemia/reperfusion injury should be expanded. 
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1.3 Aims of study
As stated in the literature survey, the phosphorylation status of proteins is determined by the actions 
of both kinases and phosphatases. The mitogen activated protein kinase (MAPK) signalling 
systems have been suggested to play a pivotal role in the outcome of ischaemia/reperfusion. 
However, little is known about the putative regulatory role of the protein phosphatases in 
ischaemia/reperfusion as well as in preconditioning. We thus hypothesized that the balance 
between the activation state of the kinases and the induction of phosphatases may play a major role 
in determining the fate of cardiomyocytes exposed to ischaemic stress. In addition, it is proposed 
that the dual specific phosphatase, MAPK phosphatase 1 (MKP-1), is of particular significance in 
this regard since it is expressed by exposure to oxidative stress and selectively dephosphorylates 
p38 MAPK.  
 
The broad objective of this study is therefore to evaluate the role of the myocardial protein 
phosphatases in establishing the activation status of the MAPKs in ischaemia/reperfusion as well as 
in ischaemic preconditioning and to determine their contribution to cardioprotection.  
 
The specific aims are the following:  
1. Assessment of PSP and PP1 activities during sustained ischaemia and during reperfusion of 
non-preconditioned and ischaemic preconditioned hearts. 
 
2. Investigation into the significance of phosphatase activation in ischaemia/reperfusion and 
ischaemic preconditioning. This was done by the use of appropriate pharmacological agents 
administered at specific times during the experimental protocol to allow distinction between trigger 
and mediator actions. Cantharidin and okadaic acid were used as inhibitors of PP1 and PP2A, while 
dexamethasone was applied to induce MKP-1 expression. Endpoints were infarct size and 
functional recovery of isolated perfused hearts, which were correlated with activation of the MAPKs 
(ERK42/44 and p38 MAPK) and PKB/Akt, and expression of MKP-1.
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CHAPTER 2 
Materials and Methods 
2.1 Animals  
Male Wistar rats (220-250g body weight) were used for all studies and allowed free access to food 
and water until the time of experimentation. Rats were anaesthetised by intraperitoneal injection of 
pentobarbital (100mg/kg). In one series of experiments dexamethasone or an equivalent volume of 
saline was administered intraperitoneally for 10 days (3mg/kg/day) before experimentation. The 
project was approved by the Ethics committee of the University of Stellenbosch (Faculty of Medicine) 
and the investigation conforms with the Guide for the Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No. 85-23, revised 1996).  
 
2.2 Materials
The protein Serine/Threonine Phosphatase (PSP) Assay System was obtained from New England 
Biolabs. The primary antibodies for p38 MAPK, ERK42/44 and PKB/Akt as well as phospho-p38 
MAPK (Thr180/ Tyr 182), phospho-ERK42/44 (Thr 202/ Tyr 204) and phospho-PKB/Akt (Ser 473) 
were purchased from Cell Signaling Technology; the antibody MKP-1(M-18):sc-1102 was obtained 
from Santa Cruz Biotechnology. Horseradish peroxidase-labelled secondary antibody, hyperflow 
ECL and the ECL detection reagents were obtained from Amersham Biosciences. Routine 
chemicals were of Analar grade and obtained from Merck, RSA. Cantharidin, okadaic acid and 
dexamethasone were purchased from Sigma Chemical Co. Decasone Injection (4mg/ml) was 
obtained from Pharmacare Limited, Port Elizabeth, RSA.  
 
2.3 Perfusion technique
The hearts were rapidly excised and arrested in ice cold (4°C) Krebs-Henseleit bicarbonate buffer 
(KHB) containing (in mM): NaCl 119; NaHCO3 25; KCl 4.75; KH2PO4 1.2; MgSO4 0.6; NaSO4 0.6; 
CaCl2 1.25; Glucose 10; pH 7.4. Perfusion with KHB was initiated via the aorta within 1 min after 
removal of the heart from the animal by the Langendorff technique in a retrograde, non-recirculating 
manner. The buffer was oxygenated with 95% O2/5% CO2 (37 °C, pH 7.4). The left atrium was 
cannulated to allow arterial perfusion. A temperature probe was inserted into the pulmonary artery 
for constant monitoring of myocardial temperature. The temperature was maintained at 36.5ºC 
during sustained global or regional ischaemia. Global ischaemia was induced by simultaneous 
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clamping of both the aortic and left arterial cannula. Normothermic, zero-flow global ischaemia was 
utilized for the induction of ischaemic preconditioning (1x5 min or 3x5 min, alternated with 5 min 
reperfusion) as well as sustained ischaemia (20 min). Reperfusion was initiated by unclamping of 
the tube to the aortic cannula, allowing retrograde perfusion. Working rat hearts were perfused at a 
preload of 15 cm H2O and an afterload of 100 cm H2O (not electrically stimulated). After sustained 
ischaemia, hearts were subsequently reperfused for 30 min (10 min retrograde, 20 min working 
heart). Retrograde perfusion during the first 10 min of reperfusion was found to be essential , since 
it allows the hearts to stabilize after the ischaemic incident. 
Drugs were administered through a side-arm into the aortic cannula, while the heart was 
retrogradely perfused.  
Intra-aortic pressure and heart rate were monitored via a pressure transducer ( Viggo Spectromed ) 
inserted into the aortic cannula, while the coronary and aortic flow rates were measured manually. 
Mechanical activity was monitored before and after sustained ischaemia. Work performance was 
calculated according to the formula described by Kannengieser et al (260): Kannengieser formula 
0.002222 x (Aortic pressure – 11.25) x Cardiac output  
 
2.4 Determination of infarct size
A suture was passed around the main branch of left coronary artery, and the end was pulled 
through a small vinyl tube to form a snare. The coronary artery was occluded by tightening the 
snare. Ischaemia was confirmed by a reduction in coronary flow. Infarction was induced by 35 
minutes of regional ischaemia which was then followed by 30 min reperfusion. Previous studies 
from our laboratory showed that shorting of the reperfusion period from 120 to 30 min had no effect 
on the determination of infarct size (260A). 
At the end of the experiment the silk suture around the coronary artery was securely tied and ~1 ml 
of a 0.5% Evans Blue suspension slowly injected via the aorta cannula. Hearts were frozen 
overnight before being cut into 2 mm thick slices. After defrosting, the slices were stained with 1% 
w/v triphenyltetrazolium chloride in phosphate buffer pH 7.4 at 37°C for 15 min. Slices were fixed in 
10% v/v formaldehyde solution to enhance the contrast between stained viable tissue and 
unstained necrotic tissue. The left ventricle area at risk (R) and the area of infarct (I) tissue were 
determined using computerised planimetry (Summa Sketch II; Summa Graphics). The infarct size 
was expressed as a percentage of the risk zone (I/R%).  
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2.5 Assay of protein phosphatases
Activities of myocardial protein serine/threonine phosphatases (PSP) and protein phosphatase 1 
(PP1) were determined using the commercial assay system of New England Biolabs according to 
the manufacturer’s instructions. Briefly, tissues were homogenized using a buffer containing (in 
mM): Tris-HCl 50, pH7.0: Na2EDTA 0.1; DTT 5. The homogenate was centrifuged for 10 min at 
3500 rpm and the supernatant used for the measurement of phosphatase activity. The substrate for 
the assay, Myelin Basic Protein (MyBP), was prepared by phosphorylation of serine and threonine 
residues with cAMP dependent protein kinase A in the presence of [33P] ATP. The reaction was 
terminated by adding trichloroacetic acid to precipitate the phosphoprotein, inactivate the protein 
kinase and remove the excess ATP. The PSP activity of tissue samples was then determined by 
measuring the release of inorganic phosphate from the labelled substrate in medium containing (in 
mM): Tris-HCl 50, pH 7.0; Na2EDTA 0.1; DTT 5; Brij 35, 0.01%. Brij (polyoxyethylene 23 lauryl ether) 
is a non-ionic detergent which is used for the extraction of membrane proteins. Results are 
expressed as nmol phosphatase activity/min/mg protein (one unit of protein phosphatase activity 
releases 1 nmol phosphate from MyBP per min in the standard assay of 50 ul). PP1 activity was 
determined as described above, except that the PP1 assay buffer contained 1 mM MnCl2, in 
addition to the components described above. The protein content of the supernatant was 
determined using the Bradford technique (261). 
 
2.6 Western blots
Hearts were freeze-clamped with pre-cooled Wollenberger tongs at different times during  the 
perfusion protocol and plunged into liquid nitrogen. The tissue was pulverized and homogenized 
with a Polytron homogenizer in 800 μl lysis buffer. For phospho-p38 MAPK (Thr 180/Tyr 182), 
phospho-ERK42/44 (Thr 202/ Tyr 204) and phospho-PKB/Akt (Ser 473) as well as total p38 MAPK, 
ERK42/44 and PKB/Akt, the lysis buffer contained (in mM): Tris 20 (pH 7.5); HCl 20; EGTA 1; EDTA 
1; sodium orthovanadate 1; sodium pyrophosphate 2.5; NaCl 150; β-glycerophosphate 1; 1% Triton 
X-100; phenylmethyl sulphonyl fluoride (PMSF) 0.3; aprotinin 10 μg/ml and leupeptin 10 μg/ml. For 
MKP-1, the lysis buffer contained (in mM): Hepes 50 (pH 7.5); EGTA 10; EDTA 10; 0.5% Triton 
X-100; phenylmethyl sulphonyl fluoride (PMSF) 1; aprotinin 2.5 μg/ml and leupeptin 2.5μg/ml, pH 
7.4. Samples were centrifuged at 1000 g for 10 min to obtain the supernatant which was used for 
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Western blotting. The protein content was determined using the Bradford technique. The tissue 
lysates were diluted in Laemmli sample buffer, boiled for 5 min. For each sample, 10 μg of protein 
for p38 MAPK and ERK42/44; 30ug for PKB/Akt; 50 μg for MKP-1 were loaded separately onto 
polyacrylamide gels (12% for p38 MAPK, ERK42/44 and MKP-1; 10% for PKB/Akt) using the 
Bio-RAD Mini-PROTEAN II System. The separated proteins were transferred to a PVDF membrane 
(Immobilon® P, Millipore) and stained with Ponceau Red for visualization of proteins. To assess the 
quality and quantity of the transfer, the membranes were laser-scanned and densitometrically 
analyzed (UN-SCAN-IT, Silkscience). Non-specific binding sites on the membranes were blocked 
with 5% fat-free milk in Tris-buffered saline- 0.1% Tween 20 (TBST). The amount of protein as well 
as activated enzyme were visualized with the appropriate primary antibody. The membranes were 
probed with polyclonal primary antibodies: 1:1000 dilution for phospho-p38 MAPK (Thr 180/Tyr 182), 
phospho-ERK42/44 (Thr 202/ Tyr 204) and  phospho-PKB/AKT (Ser 473) as well as total p38 
MAPK,ERK42/44 and PKB/Akt; 1:500 dilution for MKP-1(M-18):sc-1102. Membranes were 
subsequently washed with large volumes of TBST (2×1 min and then 3×5 min) and the immobilized 
primary antibody conjugated with a diluted horseradish peroxidase-conjugated antirabbit antibody 
(1:4000). After thorough washing with TBST, membranes were covered with ECLTM detection 
reagents and exposed to an autoradiography film (Hyperfilm ECL, RPN 2103) to detect light 
emission via a non-radioactive method. Films were densitometrically analyzed (UN-SCAN-IT, 
Silkscience) and the values obtained normalized to the corresponding controls. 
 
2.7 Experimental protocols  
In all groups, hearts were stabilized for 15 min retrograde perfusion, and then perfused in the 
working heart mode for 15 min. Hearts were preconditioned with one or three cycles of 5 min global 
ischaemia interspersed with 5 min reperfusion (preconditioning, 1xPC and 3xPC) or perfused 
retrogradely for 30 min (non-preconditioning, N-PC), equal in duration to the total time needed to 
precondition hearts with ischaemia. All hearts were then subjected to 20 min sustained global 
ischaemia or 35 min regional ischaemia followed by 30 min reperfusion (10 min retrograde, 20 min 
working heart ) (see protocol I, page 28). In addition, one group was subjected to 15 min sustained 
global ischaemia followed by 30 min reperfusion. Protocols for drugs administration will be 
described in Chapter IV and V.  
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2.8 Statistics
All values are expressed as mean ± standard error (S.E). Multiple comparisons were made by 
one-way analysis of variance (ANOVA) followed by the post-hoc Bonferroni test. When two groups 
were compared, Student’s t-test was used. Statistical significance was set at p < 0.05. A minimum 
of 6 rats were used per experimental group.  
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CHAPTER 3 
 
Effect of Ischaemia/Reperfusion and Preconditioning  
on Myocardial PSP and PP1 Activities 
 
3.1 Introduction 
As stated in the literature survey (chapter I), the mitogen activated protein kinase (MAPK) signalling 
systems have been suggested to play a pivotal role in the outcome of ischaemia/reperfusion. 
However, little is known about the putative regulatory role of the protein phosphatases in 
ischaemia/reperfusion as well as in preconditioning. It was thus hypothesized that the balance 
between the activation state of the MAPK and the induction of phosphatases may play a major role 
in determining the fate of cardiomyocytes exposed to ischaemic stress.  
 
Relatively few studies have been done on phosphatases in this scenario. PP1 and PP2A are 
present in the heart, with the amount of PP2A being ~3 times higher than that of PPI (236). PP2A is 
also present in isolated rat cardiomyocytes (237). Most, if not all, studies on phosphatase 
involvement in ischaemia/reperfusion, employed phosphatase inhibitors. The interpretation of these 
results is often complicated by the lack of specificity of many of these inhibitors. However, as far as 
we know, measurement of phosphatase activity during sustained ischaemia of preconditioned and 
non-preconditioned hearts was only done in one study (239), showing a decline in the activity of 
both PP1 and PP2A during ischaemia, but no difference between the groups. Although MAPKs and 
PKB/Akt activities during a preconditioning protocol were studied by several workers (207, 208, 262, 
263), including ourselves (242, 246), only PTEN activation in phosphatases was studied during a 
preconditioning phase (see reference 130). 
 
The aim of our first experiment was therefore to assess PSP and PP1 activities during sustained 
ischaemia and during reperfusion of non-preconditioned (N-PC) and 3 x 5 min preconditioned 
hearts (3 x PC). 
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3.2  Methods 
 
Three series of hearts were perfused, namely controls, non-preconditioned (N-PC) and hearts 
preconditioned with 3 x 5 min global ischaemia (3 x PC). Control hearts were perfused for a total of 
30 min. N-PC and 3xPC hearts were subjected to 20 min global ischaemia, followed by 30 min 
reperfusion (see protocol I). Hearts were freeze-clamped at 10, 15 and 20 min of sustained 
ischaemia and at 10, 20 and 30 min of reperfusion. 
 
 
3.3  Results
 
Table 1 shows there were no differences in PSP and PP1 activities after 10, 15, 20 minutes 
sustained ischaemia or after 10, 20, 30 minutes reperfusion (p > 0.05) in both N-PC and 3 x PC 
hearts. In addition, PSP and PP1 activities in N-PC and 3 x PC hearts at all these time internals did 
not differ significantly from their respective control values. 
 
In summary, the data showed that the PSP and PP1 activities did not differ between 
non-preconditioned and 3 x 5 min preconditioned hearts during both sustained ischaemia and 
during reperfusion. 
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Protocol I
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PSP and PP1 activities of non-preconditioned and preconditioned hearts during 
sustained global ischaemia and reperfusion. 
PSP 
(units/min/mg) 
PP1 
(units/min/mg)
PSP: protein serine/threonine phosphatases;  PP1: protein phosphatase 1, GI: sustained global ischaemia; Rep: reperfusion; 
PSP and PP1 activities were expressed as units/min/mg (1 unit of phosphatase activity releases 1 nmol phosphate from 
MyBP per min in a standard assay). Data are means ± SE. For more information about protocols, see protocol I. 
Table 1
3xPC
1
3
N-PC
4.333.904.79±0.704.56±0.4730'
2.823.345.05±0.63 4.87±0.60 20'
4.50 4.194.87±0.29 4.93±0.45 10'
(n=2)(n=6)
3.69±0.60 3.48±0.50 4.05±0.47 4.28±0.67 20'
3.21±0.38 3.36±0.40 4.21±0.75 4.31±0.63 15'
3.48±0.28 3.87±0.50 4.64±0.57 4.73±0.66 10'
(n=8)(n=6)
PCN-PCControl
3.79±0.34
PCN-PCControl    
4.26±0.28
Time(min)
GI
Rep
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3.4  Discussion
 
Previous studies from our laboratory (242, 243, 246) and as well as those from others (262-264) 
showed that the major subgroups of the MAPK signalling pathway, viz JNK (265, 266), ERK42/44 
(262, 264, 267) and p38 MAPK (242, 263, 266) are activated by short episodes of 
ischaemia-reperfusion, as occurs during an ischaemic preconditioning protocol. In particular, p38 
MAPK has been studied as a candidate kinase in the cardioprotection elicited by preconditioning. 
Our own results indicated attenuation of p38 MAPK activation during both sustained ischaemia and 
reperfusion to be associated with cardioprotection (242). However, the role of p38 MAPK as a 
mediator of protection during sustained ischaemia, is still controversial, since increased activation of 
the kinase during sustained ischaemia of preconditioned hearts has also been reported (239A). The 
reason(s) for this discrepancy need to be established, but species differences (rat vs. rabbit) may 
play a role. 
 
Should our postulated hypothesis hold true, it is to be expected that upregulation of phosphatase 
activity during ischaemia/reperfusion may contribute to attenuation of p38 MAPK activation, seen in 
previous experiments (242). The results presented in Table 1 shows that it is unlikely that 
upregulation of the protein serine/threonine phosphatasis (PSP) and more particularly PP1 are 
involved in the changes seen. In fact, neither ischaemia nor reperfusion, for 20 and 30 min 
respectively, had any effect on the activities of these phosphatases, and values obtained were 
similar to those of control hearts.  
 
The possibility exits that the reperfusion times used in this study were too short and that changes 
may occur after longer periods of reperfusion. This, however, remains to be determined.  
 
As far as we are aware, the effect of ischaemic preconditioning on PP1 and PP2A activity during 
sustained ischaemia but not reperfusion was studied by only one other group, namely Weinbrenner 
et al (239), using isolated rabbit hearts as well as cardiomyocytes. In their model, a time-dependent 
significant decline in PP1 activity was observed during 60 min sustained ischaemia, with very little 
change in PP2A activity. As was also reported by Weinbrenner and coworkers (239), we did not 
observe differences between the phosphatase activity of non-preconditioned control and 
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preconditioned hearts subjected to 20 min sustained global ischaemia (Table 1). Phosphatase 
activity has not been studied during reperfusion after sustained ischaemia and remains to be 
established.  
 
In contrast to these negative findings, Ladilov and coworkers (see reference 250) suggested that 
PP1 was a mediator of hypoxic preconditioning of the isolated heart, since the inhibitor cantharidin 
(used at a concentration which inhibits both PP1 and PP2A) was found to abolish hypoxic 
preconditioning-induced protection. 
 
Finally, although our study thus far could not provide evidence for increased phosphatase activation 
by ischaemic preconditioning, it has to be acknowledged that only two phosphatase groups were 
evaluated in this study. In view of the size, structural diversity and complexity of the phosphatase 
family, it is possible that other phosphatases may be involved in the response of the myocardium to 
ischaemia. In addition, in view of Ladilov's (see reference 250) observations, the role of at least PP1 
needs to be reinvestigated. 
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CHAPTER 4 
 
Manipulation of PP1 and PP2A Activity in Ischaemic Preconditioning: Effects on Mechanical 
Recovery and Kinase Activation Patterns during Reperfusion 
 
4.1 Introduction
In view of the negative results obtained thus far (see Chapter III) as well as the size of the 
phosphatase family, which makes identification of the involvement of a specific phosphatase 
extremely difficult (in view of the sheer volume of experimental work involved), it was decided to 
focus on two phosphatase inhibitors to further elucidate the putative roles of PP1 and PP2A in 
ischaemia/reperfusion and preconditioning. PP1 and PP2A account for >90% of all serine/threonine 
dephosphorylation reactions (268) and are expressed in all tissue types, participate in a large 
variety of cellular activities and are involved in numerous cell signalling pathways, also in cardiac 
myocytes (237).  
 
In this study, we used cantharidin and okadaic acid to differentiate between these two 
phosphatases. Cantharidin has an IC50 for PP1 of 10-6M, for PP2A of 10-7M. To inhibit both PP1 and 
PP2A, we used the drug at a concentration of 5 μM. Okadaic acid has an IC50 for PP1 of 10-7M, for 
PP2A of 10-9M. To inhibit PP2A only, we used okadaic acid at a concentration of 7.5 nM. The effects 
of these drugs on cardioprotection were evaluated by administration of the drugs in N-PC and PC 
hearts. Mechanical recovery during reperfusion, infarct size as well as the activation patterns of 
PKB/Akt, p38 MAPK and ERK42/44 during reperfusion were used as endpoints. 
4.2 Methods
For studies on functional recovery during reperfusion and kinase activation, hearts were subjected 
to 20 min global ischaemia followed by 30 min reperfusion. For evaluation of infarct size, hearts 
were subjected to 35 min coronary ligation (to obtain a reproducible infarct) and 30 min reperfusion. 
For Western blotting, hearts were freeze-clamped as follows: (1) During the PC protocol: at the end 
of 5 min ischaemia and at the end of 5 min reperfusion (before onset of 20 min sustained 
ischaemia); (2) during reperfusion: 5 and 15 min after 20 min sustained ischaemia.   
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Drug treatments (protocol II) 
Isolated rat hearts were randomly assigned to one of the following treatment groups (n≥ 6 per 
group). Drugs used were cantharidin (5 µM) and okadaic acid (7.5 nM). Cantharidin was dissolved 
in absolute ethanol (final concentration 0.5% in perfusate), while okadaic acid was dissolved in 
distilled water. N-PC and PC protocols are described before (see protocol I) 
(1) Drugs administered before 15 min or 20 min sustained global ischaemia in N-PC hearts.  
N-PC hearts were treated with a drug for 10 minutes before 15 or 20 min sustained global 
ischaemia (without washout), followed by 30 min reperfusion (protocols 2,4).  
(2) Drugs administered during PC phase before 20 min sustained global ischaemia. 
1xPC hearts received the drug for 5 min before and 5 min after one 5-min period of global ischemia, 
then subjected to 20 min sustained global ischaemia followed by 30 min reperfusion 
(Drug+1PC+Drug, protocol 7); in some hearts the drug was washed out after the preconditioning 
ischaemia, before being subjected to 20 min sustained global ischaemia and 30 min reperfusion 
(Drug+1PC, protocol 8). 3xPC hearts were treated with drugs for 5 min before each three 5-min 
periods of global ischemia, then subjected to 20 min sustained global ischaemia followed by 30 
min reperfusion (Drug+3PC, protocol 12).  
(3) Drugs administered during reperfusion after 20 min sustained global ischaemia. 
N-PC, 1xPC or 3xPC hearts received the drug during the first 10 minutes of reperfusion after 20 
min sustained global ischaemia, followed by 20 min reperfusion in the working mode (N-PC 
R+Drug, 1PC R+Drug and 3PC R+Drug, protocols 5, 9, 11). 
(4) Drugs administered in N-PC protocol or during PC phase before 35 min sustained 
regional ischaemia. 
N-PC hearts were treated with a drug for 10 minutes before 35 min sustained regional ischaemia 
(without washout), followed by 30 min reperfusion (protocol 14). In 1xPC hearts, drugs were given 
for 5 min before and 5 min after one 5-min period of global ischemia (protocol 17), in some hearts 
the drug was washed out after the preconditioning ischaemia (protocol 18) and then subjected to 
35 min sustained regional ischaemia and 30 min reperfusion.  
(5) Drugs administered during reperfusion after 35 min sustained regional ischaemia. 
N-PC or 1xPC hearts were given the drugs during first 10 minutes of reperfusion after 35 min 
sustained regional ischaemia, followed by 20 min reperfusion in the working mode (protocols 15 
and 19). 
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Protocol II
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4.3 Results 
4.3.1 Preliminary studies 
In preliminary studies, when hearts were subjected to 15 min sustained global ischaemia in N-PC 
protocol, all hearts recovered during 30 min reperfusion (see Table 3); when hearts were subjected 
to 25 min sustained global ischaemia in 3xPC protocol, almost all hearts were failed during 30 min 
reperfusion (data not shown). 
In view of these results, it was decided to limit the period of sustained global ischaemia to 20 min. 
4.3.2 Effect of ischaemia/reperfusion and ischaemic preconditioning on cardiac mechanical 
recovery during reperfusion
Table 2 and Fig 1 show that exposure of non-preconditioned hearts to 20 minutes sustained global 
ischaemia caused a significant reduction in all parameters of mechanical function measured during 
30 min reperfusion, compared to values obtained before ischaemia (p < 0.05). A significant 
decrease in AO, CO and TW compared to values obtained before ischaemia (p < 0.05) was also 
seen in preconditioned (1xPC and 3xPC) hearts. In these series Psp, HR and CF remained 
unchanged (p > 0.05).  
However, comparison of values obtained during reperfusion of N-PC and PC hearts, showed that 
both 1xPC and 3xPC caused a significant increase in CF, AO, CO, Psp, HR and TW when 
compared with non-preconditioned hearts (p < 0.05). The post-ischaemic functional recovery of AO, 
CO and TW was also significantly higher in 3xPC than in 1xPC hearts (p < 0.05).   
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Effects of ischaemia/reperfusion and ischaemic preconditioning on   
mechanical performance of the isolated rat heart
Table 2
Data are means ± SE; numbers in parentheses indicate number of hearts.
CF: coronary flow (ml/min)   AO: aortic output (ml/min)   CO: cardiac output (ml/min)  
Psp: peak systolic pressure (mmHg)   HR: heart rate (beats/min)   TW: total work (mW) 
* P < 0.05 1xPC vs N-PC 
# p < 0.05 3xPC vs N-PC 
&p < 0.05 3xPC vs 1xPC
† p < 0.05 vs Before ischaemia
8.52±0.57#&†295±15# 89±3# 42.7±1.5#&†29.3±1.1#&†13.3±0.9# 3xpc (22)
5.80±0.49*†276±11* 79±1* 33.2±2.5*†20.6±2.3*†12.5±0.7* 1xpc (17)
1.67±0.45 †128±32 †39±10 †9.5±2.5 †3.9±1.3 †5.6±1.4 †N-pc (22)
12.43±0.18 303±3 92±1 59.6±0.7 44.4±0.5 15.1±0.3 All (61)
TwHRPspCOAOCFProtocol
Before
ischaemia
After
ischaemia
1xPC 
3xPC
1
2
3
N-PC
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Fig 1. Work performance during reperfusion after 20 
min sustained global ischaemia of N-PC and PC hearts. 
Numbers of hearts and abbreviations as in Table 2.Data 
expressed as means ± SE. 
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4.3.3 Effects of cantharidin
Cantharidin (5 µM) was added to the perfusate before and after sustained global ischaemia of N-PC 
and PC hearts (see protocol II). 
4.3.3.1 Post-ischaemic functional recovery of non-preconditioned hearts
In a preliminary study, hearts were pretreated for 10 min with cantharidin (5 µM) or okadaic acid (7.5 
nM) before being subjected to 15 min sustained global ischaemia (Drug+N-PC,15’GI, see protocol 
II 2). This caused a significant reduction in AO, CO, and TW (p < 0.05, Table 3, Fig 2.1,2.2) during 
reperfusion when compared with untreated N-PC(15’GI) hearts. CF, Psp and HR were unaltered (p 
> 0.05). 
In follow-up studies, cantharidin (5uM) administered for 10 min before 20 min sustained global 
ischaemia (Can+N-PC, protocol II 4), caused complete mechanical failure during reperfusion and 
no measurements could be made. When cantharidin was added during first 10 min of reperfusion 
after 20 min sustained global ischaemia (N-PC R+Can, protocol II 5), there was no effect on any of 
the parameters of mechanical activity during reperfusion when compared with untreated N-PC 
hearts (p > 0.05, Table 3). 
4.3.3.2 Post-ischaemic functional recovery of preconditioned hearts. 
In these studies, cantharidin (5 µM) was added to the perfusate during the preconditioning phase 
and during reperfusion of preconditioned hearts (see protocol II: 7-12). Except for CF, HR and Psp 
in 1xPC, 3xPC and 1xPC R+Can as well as all values in 3xPC R+Can hearts, all parameters of 
mechanical function during reperfusion were significantly reduced in all groups when compared with 
values obtained before induction of ischaemia. 
Table 3 shows that cantharidin (5 µM) added 5 min before and 5 min after one ischaemic episode 
(Can+1PC+Can, see protocol 7) or 5 min before each of three 5-min periods of global ischemia 
(Can+3PC, protocol 12), significantly abolished cardiac mechanical recovery (CF, AO, CO, Psp, HR, 
TW) during reperfusion after 20 min sustained global ischaemia compared to preconditioned hearts 
without cantharidin pretreatment (protocol 6, 10). However when cantharidin (5 µM) was 
administered only 5 min before the 5 min global ischaemia and washed out (Can+1PC, protocol 8), 
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only the aortic output was significantly reduced (Can+1PC: 10.4±3.8 vs. 1xPC: 20.6±2.3, p < 0.05, 
Fig. 3), but no marked changes in CF, CO, Psp, HR, TW compared to 1xPC hearts without 
cantharidin pretreatment (protocol 6). This indicated that the effects of cantharidin can be 
attenuated by washing out the drug before the onset of sustained global ischaemia.  
Cantharidin (5 µM) added during first 10 min of reperfusion in 1xPC hearts (1PC R+Can, see 
protocol 9), had no effect on cardiac mechanical recovery (CF, AO, CO, Psp, HR,TW) compared 
with 1xPC hearts without cantharidin treatment, respectively (p > 0.05), but cantharidin(5µM), when 
added during the first 10 min of reperfusion in 3xPC hearts (3PC R+Can), significantly increased 
postischaemic CF, AO, CO (p < 0.05) and TW (0.05 < p < 0.1) compared with 3xPC hearts without 
cantharidin treatment. 
In summary, cantharidin added during preconditioning phase abolished functional recovery during 
reperfusion induced by both 1xPC and 3xPC, while cantharidin administered during reperfusion 
only, had no deleterious effects. In fact, an increased functional recovery was seen in 3xPC hearts 
which received the drug during early reperfusion. 
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Effect of cantharidin (5µM) on functional recovery 
after sustained global ischaemia of N-PC and PC hearts
Table 3
(1) Protocols
N-PC
N-PC R+Can
1xPC 
1PC R+Can
Can+1PC
Can+3PC
Can+1PC+Can
3xPC
3PC R+Can
20’GI
N-PC (15GI)
Can+N-PC (15GI)
1
2
3
5
6
7
8
9
10
11
12
15’GI
For more information about protocols, see protocol II. 
4 Can+ N-PC
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Table 3
Abbreviations: as in Table 2. Data are means ± SE. n = 6 per group.
10.14±0.45♦٭324±1582±254.7±1.8&♦36.8±0.9&♦17.8±1.3&3PC R+Can
0.20±0.20 •†0 •†9±9 •†6.4±0.9 •†0 •†6.4±0.9 •†Can+3PC
8.52±0.57†295±15 89±3 42.7±1.5†29.3±1.1†13.3±0.9 3xPC
7.53±0.85†297±8 82±1 40.7±3.9†25.7±3.2†15.0±1.3 1PC R+Can
3.76±0.98†269±22 79±2 20.4±5.3†10.4±3.8#†10.0±1.6†Can+1PC
1.55±0.52#†120±57#†45±12#†12.4±1.9#†3.4±1.6#†9.0±0.4#†Can+1PC+Can
5.80±0.49†276±11 79±1 33.2±2.5†20.6±2.3†12.5±0.7 1xPC
1.85±0.85†146±66†38±17†10.8±4.9†3.8±2.7 †7.0±3.4†N-PC R+Can
1.67±0.45†
0.00 †
128±32†
0.00 †$
39±10†
0.00 †$
9.5±2.5 †
0.00 †
3.9±1.3 †
0.00 †
5.6±1.4†
0.00 †
N-PC
Can+N-PC ‡
1.82±0.82 *†162±59†49±14†13.7±3.1*†3.6±2.3 *†10.1±1.2†Can+N-PC(15'GI)
6.75±0.33†291±1380±1 37.7±1.7†25.3±1.2†12.3±0.8 N-PC(15'GI)
12.43±0.18 303±3 92±1 59.6±0.7 44.4±0.5 15.1±0.3 All 
TwHRPspCOAOCFProtocols
Before
iachaemia
After
ischaemia
* P < 0.05 vs N-PC(15’GI)
$ P < 0.05 vs N-PC(20’GI)
(2) Functional recovery
# P < 0.05 vs 1xPC
• P < 0.05 vs 3xPC
‡ Cantharidin added to the perfusate before 20 min GI caused complete mechanical failure during reperfusion 
and no measurements could be made.
† p < 0.05 vs Before ischaemia &P < 0.05 vs 3xPC
٭ 0.05 < P < 0.1 vs 3xPC
♦ P < 0.05 vs 1xPC R+Can
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Fig 2.1. Effect of cantharidin (5 µM) pretreatment on 
functional recovery after 15 min sustained global ischaemia
followed by 30 min reperfusion. Abbreviations as in Table 2. 
Data are means ± SE, n = 6 per group.
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1
2
Fig 2.2. Effect of okadaic acid (7.5 nM) pretreatment on 
functional recovery after 15 min sustained global ischaemia
followed by 30 min reperfusion. Abbreviations as in Table 2.
Data are means ± SE, n = 5 per group.
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Fig 3. Effect of cantharidin (5 µM) treatment on cardiac function during 30 min reperfusion after 20 min global ischaemia. 
Abbreviations as in Table 2. C= Untreated. Data expressed as means ± SE, n= 6 per group. see protocol II. 
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4.3.3.3 Effects of cantharidin on infarct size.  
Infarct size is expressed as a percentage of the area at risk in rat hearts. For these studies, hearts 
were subjected to 35 min regional ischaemia , followed by 30 min reperfusion (protocol II 13-19).  
When cantharidin (5 uM) was administered for 10 min before 35 min sustained regional ischaemia 
in N-PC hearts (protocol II 14), there was no change in infarct size versus untreated N-PC hearts. 
In 1xPC hearts, infarct size was significantly reduced to 18.4±1.9% from 36.2±2.1% in N-PC hearts 
(p < 0.05, Fig. 4). Cantharidin (5 µM) added 5 min before and 5 min after one 5-min ischaemic 
preconditioning protocol (Can+1PC+Can, protocol 17), showed a significant increase in infarct size 
(Can+1PC+Can: 27.8±4.1% vs. 1xPC:18.4±1.9%, p < 0.05, Fig 4), which did not differ from N-PC 
hearts (36.2±2.1%, p > 0.05). Washout of cantharidin during a 1xPC protocol (Can+1PC) retained 
the beneficial effect of 1xPC (Can+1PC: 24.3± 2.1% vs. 1xPC: 18.4±1.9%, p > 0.05).  
Cantharidin (5 µM) added during the first 10 min of reperfusion (N-PC R+Can or 1PC R+Can, 
protocols 15, 19), had no influence on infarct size of N-PC or PC hearts (N-PC R+Can: 31.0±3.3% 
vs. N-PC: 36.2±2.1 and 1PC R+C: 17.6±1.1% vs. 1xPC: 18.4±1.9%). Thus the presence of 
cantharidin (5 µM) for the first 10 min of reperfusion did not abrogate the PC-induced reduction in 
infarct size. Cantharidin was also without effect on infarct size of N-PC hearts when added before or 
during reperfusion. 
In these studies, the area at risk did not differ between the groups. The averaged value was 
46.8±4.3%. 
In summary, administration of cantharidin during the preconditioning phase, abolished the beneficial 
effects of this intervention on infarct size, while administration during reperfusion was without effect 
on infarct size in both N-PC and PC hearts. 
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# P < 0.05 vs N-PC
Fig 4. Effect of cantharidin (5µM) on infarct size (IS) of hearts subjected to 35 min coronary ligation and 30 min 
reperfusion. Infarct size expressed as a percentage of the ischaemic (risk) zone. Data are means ± SE, n ≥ 6 per group, 
see protocol II. 
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4.3.3.4 Effect of cantharidin on kinase activation before sustained global ischaemia (GI).
To evaluate events before the onset of sustained global ischaemia, rat hearts were exposed only to 
1 x 5 min global ischaemia (1xPC), then freeze-clamped before sustained ischaemia in the 
presence or absence of cantharidin. All values obtained were normalized with untreated hearts. The 
results showed that 1x 5 min ischaemia (5’GI) increased p38 MAPK activity, but when reperfused 
for 5 min (5’GI5’R), the activation of p38 MAPK is reduced (au. 5’GI 1.54+0.11 vs. 5’GI5’R 1.00+ 
0.11). There were no changes in ERK42/44 and PKB activities in 5’GI5’R versus 5’GI without 
reperfusion. 
Since cantharidin was dissolved in ethanol, vehicle control studies were performed where ethanol 
(0.5%) alone was administered for 10 min before or after 20 min sustained ischaemia and hearts 
freeze-clamped after 5 and 10 min reperfusion. Assay of kinase activities showed that ethanol has 
no effect on kinase activation when administered before sustained ischaemia. However, when 
ethanol added during reperfusion, a slight but significant PKB activation was observed, while p38 
MAPK and ERK42/44 were not affected (Van Vuuren and Lochner unpublished data). 
It is important to note that administration of cantharidin (5 uM) before 5 min ischaemia was sufficient 
to significantly activate all the kinases involved (Figs 5 and 6) and that they remained activated until 
the time that the heart goes into long ischaemia (au. p38 MAPK: 5’Can5’GI 1.97+0.46, 
5’Can5’GI5’R 3.99+0.28 vs. 5’GI5’R 1.00+0.11, p < 0.05, respectively; ERK44: 5’Can5’GI 1.58+0.23, 
5’Can5’GI5’R 1.55+0.09 vs. 5’GI5’R 1.00+0.03, p < 0.05, respectively; PKB: 5’Can5’GI 1.66+0.23,  
5’Can5’GI5’R 1.74+0.25 vs. 5’GI5’R 1.00+0.25, 0.05 < p < 0.1, respectively). Thus, the activations 
of these kinases were sustained even after 5 min reperfusion. It was concluded that cantharidin 
pretreatment (i.e. during the preconditioning phase) caused increased phosphorylation of all three 
kinases which persisted until the onset of sustained ischaemia. 
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Fig 5. Effect of cantharidin (5 µM) treatment on phosphorylation of p38 MAPK and PKB without sustained 
ischaemia. AU: arbitrary units. Data are means ± SE, n = 6 per group. See protocol II.
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Fig 6. Effect of cantharidin (5 µM) 
treatment on phosphorylation of ERK42/44 
without sustained ischaemia. AU: arbitrary 
units. 
Data are means ± SE, n = 6 per group. 
See protocol II.
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4.3.3.5 Effect of cantharidin on kinase activation during reperfusion. 
 
Preliminary studies 
To determine the optimal time of reperfusion for assessment of kinase activity, a preliminary series 
of experiments was done. These hearts were freeze-clamped at 5, 10, 15, 20 or 30 min of 
reperfusion (n= 3 hearts/series). Subsequent Western blotting showed that PKB/Akt, in particular, 
was maximally activated at 5 min reperfusion, while no changes were seen after 20 min. It was 
therefore decided to freeze-clamp hearts after 5 and/or 15 min reperfusion. 
 
Total p38 MAPK, ERK42/44 and PKB were evaluated at 5, 15 and 30 min reperfusion, and were 
found to be unchanged (data not shown). In view of the unchanged total values for the above 
kinases, the corresponding blots were not included in the results section. 
 
Also in a preliminary study, pretreatment of N-PC hearts with cantharidin before 15 min sustained 
global ischaemia (Can+N-PC 15’GI) caused a significantly increased phosphorylation of p38 MAPK 
after 15 min reperfusion (a.u 1.69±0.15 vs. 1.00 in N-PC 15’GI, p < 0.05, Fig. 7), but no marked 
difference in ERK42/44 phosphorylation (a.u 1.41±0.26/1.40±0.29 vs. 1.00 in N-PC 15’GI, 
respectively, p > 0.05).  
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Effect of cantharidin on phosphorylation of p38 MAPK. 
 
When cantharidin (5 µM) was administered during the preconditioning protocol (1x5 min or 3x5 min) 
before 20 min sustained global ischaemia, there was a twofold increase in p38 MAPK 
phosphorylation at 5 min and 15 min reperfusion (a.u Can+1PC+Can: 5 min 2.30±0.17 and 15 min 
1.98±0.25; Can+3PC: 5 min 2.08±0.40 and 15 min 2.36±0.20, p < 0.05, respectively, vs. untreated 
control, Fig. 8).  
 
Cantharidin (5 µM) administered during 5 min reperfusion in preconditioned (PC R+Can) and 
non-preconditioned (N-PC R+Can) hearts, did not change phosphorylation of p38 MAPK compared 
to untreated N-PC or PC hearts, respectively (a.u 1PC R+Can: 0.97±0.07; 3PC R+Can: 1.29±0.18; 
N-PC R+Can: 0.88±0.13, vs. untreated hearts 1.00, p > 0.05); after 15 min reperfusion, there were 
slight but no significant increases in p38 MAPK activity (a.u 1PC R+Can: 1.35±0.26; 3PC R+Can: 
1.45±0.27; N-PC R+Can: 1.66±0.29, p > 0.05, Fig. 8). 
 
Effect of cantharidin on phosphorylation of ERK42/44. 
 
Cantharidin (5 µM) administered during the 1xPC phase (Can+1PC+Can, protocol 7) before 20 min 
sustained global ischaemia, reduced phosphorylation of ERK42/44 during 5 min reperfusion (a.u 
0.34±0.10/0.71± 0.12) compared to untreated 1xPC hearts, but only ERK42 activity was markedly 
different (p < 0.05, Fig. 9). After 15 min reperfusion, no changes were observed. Cantharidin (5 µM) 
added during 3xPC protocol (Can+3PC, protocol 12), had no significant effects on ERK42/44 
activity during 5 and 15 min reperfusion. 
 
When cantharidin (5 µM) was administered during reperfusion (PC R+Can and N-PC R+Can), there 
were slight but not significant increases of ERK42/44 phosphorylation after 5 min reperfusion (a.u 
1PC R+Can: 1.34±0.12/1.49±0.19; 3PC R+Can: 1.22±0.03/1.23±0.07; N-PC R+Can: 
1.44±0.20/1.46±0.09, p > 0.05, Fig. 9) compared to untreated N-PC or PC hearts, respectively. 
After 15’ min reperfusion, ERK42/44 activity had significantly increased in 3PC R+Can (a.u 
1.94±0.32/2.08±0.54) and in N-PC R+Can (a.u 1.83±0.16/2.33±0.11), p < 0.05, respectively. During 
10 min reperfusion, in 1PC R+Can also increased ERK42/44 activity (a.u 1.58±0.24/1.60±0.23), but 
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only ERK44 activity (a.u 1.60±0.23) was markedly increased versus untreated 1xPC hearts (p < 
0.05, Fig 9). 
 
Effect of cantharidin on phosphorylation of PKB. 
 
When cantharidin (5 µM) was administered during reperfusion or during the preconditioning 
protocol, there were significant increases in PKB phosphorylation during 5 min reperfusion (a.u 1PC 
R+Can: 1.85±0.16 ; Can+1PC+Can: 1.80±0.49 ; Can+3PC: 1.68±0.30, p < 0.05 vs untreated hearts, 
respectively, Fig. 10). After15 min reperfusion, only 3PC R+Can showed a marked increase in PKB 
activity (a.u 2.23±0.35, p < 0.05). There was no change in PKB phosphorylation in N-PC R+Can 
protocol after 5 and 15 min reperfusion.  
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Fig 8. Effect of cantharidin (5 µM) treatment on phosphorylation of p38 MAPK during reperfusion. AU: arbitrary 
units. C= Untreated. 5’ and 15’ indicate time of reperfusion. Data are means ± SE, n = 6 per group. See protocol II.
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Fig 9. Effect of cantharidin
(5 µM) treatment on 
phosphorylation of 
ERK42/44 during 
reperfusion. AU: arbitrary 
units. C= Untreated. 
5’,10’,15’ indicate time of 
reperfusion. Data are
means ± SE, n = 6 per 
group. See protocol II.
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Fig 10. Effect of cantharidin (5 µM) treatment on phosphorylation of PKB during reperfusion. AU: arbitrary units. C= 
Untreated. Data are means ± SE, n = 6 per group. See protocol II.
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4.3.4 Effect of okadaic acid  
In view of the fact that very similar results were obtained in one and three cycle preconditioned 
hearts when treated with cantharidin, it was decided to study the effects of okadaic acid (7.5 nM) in 
a single cycle preconditioning protocol only. 
4.3.4.1 Effect of okadaic acid on post-ischaemic functional recovery 
As observed above, when hearts were treated with okadaic acid (7.5 nM), except for Psp, HR and 
CF in 1PC R+OA protocol, all parameters of mechanical function measured during reperfusion were 
significantly less than the values obtained before induction of ischaemia (Table 4, see protocol II. 5, 
7 and 9). 
As also described before in a preliminary study, okadaic acid (7.5 nM) administered for 10 min 
before 15 min sustained global ischaemia (OA+N-PC,15’GI, protocol II 2), caused a significant 
reduction in AO, CO, and TW (p < 0.05, Fig 2.2) during reperfusion when compared with untreated 
N-PC(15’GI) hearts. CF, Psp and HR were unaltered (p > 0.05).  
In follow-up study, okadaic acid (7.5 nM) added 5 min before and 5 min after one ischaemic episode 
(OA+1PC+OA, protocol 7), significantly abolished cardiac mechanical recovery (CF, AO, CO, Psp, 
HR, Tw) during reperfusion after 20 min sustained global ischaemia, compared with untreated 1xPC 
hearts.  
Okadaic acid (7.5 nM) added during first 10 min of reperfusion in N-PC protocol (N-PC R+OA, 
protocol 5), had no effect on cardiac mechanical recovery (CF, AO, CO, Psp, HR,TW) compared 
with N-PC hearts without okadaic acid treatment (p > 0.05, Table 4); in 1xPC R+OA protocol, 
okadaic acid had significantly increased post-ischaemic AO and TW versus 1xPC untreated hearts 
(p < 0.05, Fig 11).  
In summary, in 1xPC hearts, okadaic acid added during preconditioning phase abolished 
preconditioning-induced functional recovery during reperfusion, while okadaic acid administered 
during reperfusion only, improved mechanical performance during 30 min reperfusion. In contrast to 
the preconditioned hearts, okadaic acid, when administered during the reperfusion of 
non-preconditioning hearts, was without effect on functional recovery. 
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6.75±0.33†
3.47±0.41†& 
291±13
276±34
80±1
86±2 
37.7±1.7†
18.3±2.3†&
25.3±1.2†
3.2±2.1†& 
12.3±0.8
14.3±2.3 
N-PC(15'GI)
OA+N-PC(15’GI)
9.01±0.63#†284±2090±545.2±3.5†30.8±2.7#†14.3±1.11PC R+OA
1.54±0.79*†120±75*†36±16*†10.3±4.8*†3.0±1.8*†7.3±3.3*†OA+1PC+OA
5.80±0.49†276±11 79±1 33.2±2.5†20.6±2.3†12.5±0.7 1xPC
2.73±1.22†154±69†38±17†16.0±7.2†9.2±4.1†6.8±3.1†N-PC R+OA
1.67±0.45†128±32†39±10†9.5±2.5†3.9±1.3†5.6±1.4†N-PC
12.43±0.18 303±3 92±1 59.6±0.7 44.4±0.5 15.1±0.3 All
TwHRPspCOAOCFProtocols
Effect of okadaic acid (7.5nM) on functional recovery after 20 min sustained global ischaemia of N-PC and PC hearts. 
Table 4
Before
ischaemia
After
ischaemia
* P < 0.05 vs 1xPC
# P < 0.05 vs 1xPC
Abbreviations: as in Table 2. Data are means ± SE, n = 6 per group.
N-PC R+OA
1PC R+OA
OA+1PC+OA
5
7
9
N-PC (15GI)
OA+N-PC (15GI)
1
2
15’GI
20’GI
† p < 0.05 vs Before ischaemia
& P < 0.05 vs N-PC(15’GI)
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4.3.4.2 Effects of okadaic acid on infarct size. 
Okadaic acid (7.5 nM) was administered for 10 min before 35 min sustained regional ischaemia in 
N-PC hearts (protocol II 14), there was no change in infarct size versus untreated N-PC hearts. 
In 1xPC hearts, infarct size was significantly reduced to 18.4±1.9% from 36.2±2.1% in N-PC hearts 
(p < 0.05). Okadaic acid (7.5 nM) added 5 min before and 5 min after one 5-min global ischaemic 
preconditioning protocol (OA+1PC+OA, protocol 17), showed a significant increase in infarct size 
(24.8±3.0%), which did not differ from N-PC hearts (36.2±2.1%, p > 0.05, Fig 12). Washout of 
okadaic acid during a 1xPC protocol (OA+1PC) retained the beneficial effect of 1xPC (1xPC: 
18.4±1.9% vs. OA+1PC: 21.9±2.2%, p > 0.05).  
Okadaic acid (7.5 nM) added during the first 10 min of reperfusion (N-PC R+OA or 1PC R+OA, 
protocols 14 and 19), had no influence on infarct size of N-PC and PC hearts (N-PC R+OA: 
26.9±3.9% vs. N-PC: 36.2±2.1 and 1PC R+OA: 20.4+2.1% vs. 1xPC: 18.4±1.9%, p > 0.05, Fig. 12). 
Thus the presence of okadaic acid (7.5 nM) for the first 10 min of reperfusion did not abrogate the 
PC-induced reduction in infarct size, and was also without effect on infarct size of N-PC hearts. 
However, administration of okadaic acid during a preconditioning phase, abolished the beneficial 
effects of this intervention on infarct size. 
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4.3.4.3 Effect of okadaic acid on kinase activation during reperfusion. 
In these studies, the activation status of the kinases was evaluated after 5 min reperfusion in the 
preconditioned groups. In the case of N-PC, samples were taken at both 5 and 15 min reperfusion. 
When okadaic acid (7.5 nM) was administered during preconditioning phase or during reperfusion 
in 1xPC hearts, no significant p38 MAPK and PKB phosphorylation occurred as measured after 5 
min of reperfusion (Fig 13): p38 MAPK activity (a.u 5 min 1PC R+OA: 0.87±0.21, OA+1PC+OA: 
1.10±0.07), PKB activity (a.u 5 min 1PC R+OA: 1.47±0.29, OA+1PC+OA: 0.88±0.23) compared 
with untreated 1xPC hearts. Also in N-PC hearts (N-PC R+OA), no significant p38 MAPK and PKB 
activation occurred after 5 min and 15 min reperfusion. 
When okadaic acid (7.5 nM) was administered during the PC phase (OA+1PC+OA), no marked 
ERK42/44 activity was seen after 5 min reperfusion, but when added during reperfusion in 1xPC 
protocol (1PC R+OA), had significantly increased phosphorylation of ERK42/44 phosphorylation 
after 5 min reperfusion (a.u 1.54±0.17/1.69±0.18 vs. 1.00 in untreated 1xPC hearts, p < 0.05, 
respectively, Fig 14). When administered during reperfusion of N-PC hearts, okadaic acid had no 
significant effect on ERK42/44 phosphorylation after both 5 and 15 min reperfusion. 
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Fig 13. Effect of okadaic acid (7.5nM) treatment on phosphorylation of p38 MAPK and PKB during reperfusion. AU: arbitrary 
units. C= Untreated. Data are means ± SE, n = 6 per group. See protocol II.
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4.4 Discussion 
 
As mentioned previously, it was decided to further investigate the possibility that the phosphatases 
PP1 and PP2A are involved in the cardioprotection of preconditioning.  
 
As discussed in the literature survey, PP2A directly or indirectly regulate protein dephosphorylation 
including the MAPK pathway members ERK42/44 and the pro-survival Bcl-2 protein (45, 269). 
Proteins thought to be dephosphorylated by PP1 include the pro-apoptotic Bcl-2 family member, 
Bad (38).The multiple interactions between Bcl-2 and PP1/PP2A phosphatases, may explain how 
these phosphatases control cell survival. 
 
The results obtained with the inhibitors, cantharidin and okadaic acid, suggested that these 
phosphatases may indeed play a role in the outcome of ischaemia/reperfusion. In our study, we find 
that pretreatment with the drugs before sustained ischaemia, all abolished the cardioprotection 
induced by preconditioning, but treatment after the onset of sustained ischaemia, during reperfusion, 
is still cardioprotective.  
 
Properties of inhibitors 
Both inhibitors have actions unrelated to their phosphatase inhibitory properties. Cantharidin has 
been demonstrated to act as a vasoconstrictor and positive inotrope in guinea pig (270) and human 
cardiac (271) tissue in vitro. These effects are mediated in part by cantharidin's action as a protein 
phosphatase inhibitor (272, 273). Cantharidin at 1 µM reduces the activity of purified phosphatase 
catalytic subunits by 80-90% for PP2A and by 15-35% for PP1 (273, 274). In vivo studies suggest 
that the efficiency of cantharidin to inhibit phosphatases is slightly reduced compared with that in in 
vitro studies because of the lipophobic nature of cantharidin (275). It should also be noted that 
cantharidin is an economically feasible tool to study the functional effects of PP1 and PP2A in 
perfused hearts. Okadaic acid is a potent inhibitor of PP1 and PP2A at nanomolar concentrations 
but also has tumor promoting activity in vivo. However, okadaic acid is able to interact with a variety 
of molecular targets, resulting in an overall increase in phosphorylation of regulatory proteins (see 
reference 276). Both these phosphatase inhibitors can block apoptosis induced by staurosporine, 
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and etoposide in leukemic cell lines (277, 278). 
PP1 and PP2A differ significantly in their sensitivity to phosphatase inhibitors in vitro (279, 280). The 
concentrations of phosphatase inhibitors needed to block PP1 and PP2A in cells are much higher 
than those shown to block PP1 or PP2A in vitro. The difference in concentration is presumably a 
consequence of cell permeability as well as the concentration of protein phosphatases in the cell. It 
should be kept in mind that the protein phosphatase activity such as in cell lysates in vitro does not 
reflect the true activity in cells due to partial or complete disassembly from regulatory components, 
and because of dephosphorylation and activation of phosphatase protein during analysis. The true 
activity of protein phosphatases in cells has, therefore, been difficult to measure. 
 
Endpoints 
For the purpose of this study, three endpoint were used, namely, post-ischaemic mechanical 
recovery during reperfusion, infarct size and the activation patterns of p38 MAPK, ERK 42/44 and 
PKB/Akt during ischaemia/reprefusion of the working rat heart model. Infarct size determination has 
been used as the “gold standard” in studies on preconditioning (always showing a reduction). Use 
of post-ischaemic recovery as endpoint, has proved a much more difficult endpoint to attain. Further 
more, a reduction in infarct size is not always associated with improved functional recovery and 
probably depends on the experimental model (281). However, in the globally ischaemic heart, as 
used in this study, preconditioning (1xPC and 3xPC) always resulted in a significant improvement in 
functional performance, associated with a reduction of infarct size. In addition to functional recovery 
and infarct size, activation of the reperfusion injury salvage kinase (RISK) pathway (10) has 
increasingly been used as indicator of protection. 
 
Ischaemia–reperfusion after ischaemic preconditioning has been shown to activate the pro-survival 
kinase signalling cascades, namely the phosphatidylinositol-3-OH kinase (PI3K)–Akt (7, 7A, 8) and 
MEK-1/2-ERK-1/2 (9, 9A) kinase cascades (RISK pathway), both of which have been implicated in 
cellular survival, through their recruitment of anti-apoptotic pathways of protection (282). The 
PI3K–Akt signalling cascade is activated in response to the activation of a wide range of receptors, 
including those for growth factors and G-protein-coupled receptors (282) and participates in 
numerous cellular processes by phosphorylating a diverse array of substrates, including glycogen 
synthase kinase-3b (glycogen and protein metabolism), apoptotic proteins (BAD, BAX, BIM, p53 
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and caspases), GLUT4 vesicles (glucose metabolism), transcription factors (IKK-α and Forkhead 
proteins), p70S6K, eNOS and PKC (282). These multiple signalling pathways can function as 
positive modulators of the PI3K/Akt pathway and PP2A serves as a major PKB/Akt phosphatase 
(for review see 283). 
 
The MAPKs play important roles in cell survival and apoptosis and it is clear that their regulation 
involves a dynamic interplay between kinases and phosphatases. Three distinct MAPKs pathways 
have been characterized. The extracellular signal-regulated kinase ERK1/2 pathway 
(Raf→MEK1,2→ERK1,2) is activated by mitogens via Ras and by phorbol esters via protein kinase 
C. The stress-activated MAPK pathways, c-Jun N-terminal kinase/stress-activated protein kinase 
(JNK/SAPK) (MEK kinase 1,3→MAPK kinase 4,7 [MKK4,7]→JNK1,2,3) and p38 MAPK (MAPK 
kinase kinase [MAPKKK]→MKK3,6→p38α,β,γ,δ) are activated by cellular stress, e.g., UV light, 
osmotic and oxidative stress, and inflammatory cytokines (284, 285). Despite some controversy, it is 
accepted by most that p38 MAPK and JNK signalling pathways play a proapoptotic role in 
cardiomyocytes subjected to ischaemia or oxidative stress (286-288). The dynamic balance 
between the opposing effects of ERK and JNK/p38 MAPK is therefore important in determining 
whether a cell will survive or undergo apoptosis (289). ERK protects cardiomyocytes from oxidative 
stress-induced apoptosis (9, 290, 291) and p38 MAPK promotes apoptosis (286-288). 
Phosphorylation of MAPKs results in their translocation to the nucleus, where they activate 
transcription factors by phosphorylation. 
 
Extensive biochemical, pharmacological, and genetic evidence suggests that PP1 and PP2A 
negatively regulates several of the kinases involved in the MAPK cascade. Inhibition of these 
phosphatases would allow for the continual activation of both these kinases in cell cycling (42, 283, 
292). PP1 and PP2A inhibit the activity of the ERK pathway by dephosphorylation of MEK1,2 and 
ERK1/2 (14, 283, 293). On the other hand, inhibition of PP1 and PP2A activity results in activation 
of ERK and in enhancement of AP-1-dependent gene expression (283, 293, 294). While PP2A 
regulates ERK phosphorylation, ERK has not been shown to be a substrate for PP2A, but is more 
likely a downstream target of PP2A activity (45). 
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Cantharidin and okadaic acid 
There were several major findings in our study in the in vitro rat hearts. Firstly, in isolated 
ischaemic-reperfused hearts, cantharidin added during the preconditioning phase abolished 
functional recovery during reperfusion induced by preconditioning; however, the effects of 
cantharidin can be attenuated by washing out the drug before the onset of sustained global 
ischaemia. When cantharidin was administered during reperfusion only, no deleterious effects were 
observed, but surprisely, cantharidin, when added during first 10 min of reperfusion in 3xPC hearts, 
significantly increased postischaemic CF, AO, CO (p < 0.05) and TW (0.05 < p < 0.1). Secondly, 
these observations were also reflected by the changes in infarct size. Cantharidin administered 
during preconditioning phase increased the infarct size, while its presence during reperfusion had 
no effect on this endpoint. Thirdly, the effects of the inhibitor on infarct size and functional recovery 
during reperfusion were reflected in changes in the phosphorylation of p38 MAPK, ERK42/44 and 
PKB/Akt. For example, pretreatment of N-PC hearts caused a significantly increased 
phosphorylation of p38 MAPK after 15 min reperfusion, with no activation of ERK42/44. Similarly, 
cantharidin administered during the preconditioning phase, caused a significantly increased p38 
MAPK phosphorylation at 5 min and 15 min reperfusion, and decreased phosphorylation of 
ERK42/44 during 5 min reperfusion. On the other hand, cantharidin administered during reperfusion 
did not upregulate p38 MAPK phosphorylation, but significantly increased ERK42/44 activation in 
1xPC hearts after 10 min reperfusion, in 3xPC and N-PC hearts after 15 min reperfusion (Fig 9). 
When cantharidin was administered during the preconditioning phase, there were significant 
increases in PKB phosphorylation at 5 min reperfusion. When added during reperfusion, a marked 
increase in PKB activity was observed in preconditioned hearts. 
It should be kept in mind that the significant increase in PKB phosphorylation during reperfusion 
may be partially due to the use of ethanol as solvent added during reperfusion. However, ethanol 
present before sustained ischaemia, did not have a confounding effect on phosphorylation of these 
kinases (p38 MAPK, ERK and PKB). 
As in the case of cantharidin, okadaic acid added during preconditioning phase abolished 
preconditioning-induced protection and showed a significant increase in infarct size, while okadaic 
acid administered during reperfusion only, was without effect. When okadaic acid was administered 
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during the preconditioning phase, no marked ERK42/44 and PKB phosphorylation occurred after 5 
min reperfusion, but okadaic acid, when added during reperfusion in 1xPC, caused significant 
phosphorylation of ERK42/44 after 5 min reperfusion. The differences between the effects of the 
two inhibitors on kinase phosphorylation may be due to the fact that cantharidin inhibits both PP1 
and PP2A, while okadaic acid selectively inhibits PP2A. 
To summarize, our data demonstrated that inhibition of PP1 and PP2A during the preconditioning 
phase abolished protective effect of preconditioning associated with activation of p38 MAPK and 
PKB, dephosphorylation of ERK42/44 and an increased infarct size, while inhibition of PP1 and 
PP2A during reperfusion improved protection in preconditioned hearts associated with activation of 
ERK42/44 (especially after 10 min and 15 min reperfusion) and PKB, but no upregulation of p38 
MAPK.  
To our knowledge, the effects of PP1 and PP2A inhibitors have not yet been studied on 
preconditioned hearts, using the working heart model. The cardioprotective effect of PP1 and PP2A 
inhibition in isolated buffer-perfused rat hearts during reperfusion may be in part mediated by its 
activation of the pro-survival kinase signalling cascades, the PI3K–Akt and MEK-1/2-ERK-1/2 both 
of which have been implicated in cellular survival, possibly through their recruitment of 
anti-apoptotic pathways of protection (282) or effects on the opening of the mitochondrial 
permeability transition pore (MPTP) (211, 212). Abolishment of ischaemic preconditioning-induced 
cardioprotection by administering the drugs during the preconditioning phase, may be attributed to 
upregulation of p38 MAPK phosphorylation during reperfusion. It is also possible that the sustained 
activation of p38 MAPK in particular, induced by administration of cantharidin, at the onset of global 
iachaemia, contributed to the mechanical failure (see Fig 5).  
Although controversial, increased phosphorylation and activation of p38 MAPK during 
ischaemia/reperfusion has been associated with a reduction in functional recovery and an increase 
in infarct size (for review see 295) and increased apoptosis in the isolated working rat heart (242). 
Our data are consistent with the view that both PP1 and PP2A exert regulatory actions at multiple 
sites of the ERK and p38 MAPK signalling pathways and the phosphorylation status of p38 MAPK, 
ERK and PKB may be mediated directly by these protein phosphatases. 
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The results obtained in this study also indicate that the timing of phosphatase inhibitor 
administration determines the outcome of the ischaemia/reperfusion injury. If added during the 
preconditioning phase, it abrogates protection, while having beneficial effect when added during 
reperfusion. Pretreatment with the inhibitor before the onset of sustained ischaemia (in the absence 
of preconditioning) also severely depressed functional recovery (see Table 3). These findings are in 
contrast with those obtained in cardiomyocytes: pretreatment with fostriecin (239, 240), calyculin A 
(245, 296) or okadaic acid was found to protect cardiomyocytes (296). An explanation for these 
contradictory findings is not readily available. However, Mackay and Mochley-Rosen (241) found 
that vanadate, a inhibitor of tyrosine phosphatase, enhanced tyrosine residue phosphorylation. As 
far as we know, the role of phosphatases in preconditioning has been studied by only one other 
group. Ladilov et.al ( see reference 250) found that both cantharidin and okadaic acid were able to 
abolish hypoxia-induced preconditioning, suggesting PP1 involvement in the triggering process. 
These findings are in agreement with our data.  
 
 
Summary 
 
Finally, in this study we observed that phosphatase inhibition during preconditioning phase 
abolishes protection while inhibition during reperfusion after sustained ischaemia either has no 
effect or enhances the cardioprotective effects of preconditioning. The exact mechanism is not clear, 
perhaps maintenance of kinases in a phosphorylated state until the onset of reperfusion is 
undesirable while phosphatase inhibition during reperfusion may extend the period of RISK 
activation and thus protect the heart. This may be an explanation for the increased functional 
recovery observed in preconditioned hearts when the inhibitor was administered during early 
reperfusion (Figs 3 and 11). The ability to manipulate and up-regulate the RISK pathway by the use 
of appropriate phosphatase inhibitors, during the early reperfusion phase may thus provide a 
potential approach to limiting reperfusion-induced cell death. 
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CHAPTER 5 
 
Role of Mitogen-Activated Protein Kinase Phosphatases (MKP-1) on Response of 
Heart to Ischaemia/Reperfusion: Effect of Dexamethasone 
 
5.1 Introduction 
 
The mitogen-activated protein kinase phosphatases (MKPs) constitute a family of 11 dual-specificity 
phosphatases that inactivate the MAPKs by dephosphorylation of specific Thr/Tyr residues. Some 
of these MKPs are often active only against specific MAPKs, although MKP-1 is able to 
dephosphorylate ERK, JNK and p38 MAPK in cell culture (14). The contribution of the MAPKs to 
cell death (78) and survival has been studied extensively (for review see 295), but it remains 
unclear whether the MKPs play a regulatory role in these processes. A recent study by Wu and 
Bennet (297) showed that in fibroblasts MKP-1 promotes cell survival by attenuating 
stress-responsive MAPK-mediated apoptosis. A previous study from our laboratory also showed 
that cardioprotection induced by long-chain fatty acids was associated with upregulation of MKP-1 
(298). 
 
It has been shown that MKP-1 preferentially inactivates p38 MAPK, then JNK and to a lesser extent 
ERK (78). Previous studies from our laboratory (242) suggested that activation of p38 MAPK during 
ischaemia and reperfusion is harmful and we hypothesized that inactivation of this kinase by 
upregulation of MKP-1 should be cardioprotective. The aim of this study was therefore to evaluate 
the effects of upregulation of this dual- specificity phosphatase on functional recovery and infarct 
size of the isolated rat heart subjected to ischaemia/reperfusion. Dexamethasone, which causes 
sustained expression of MKP-1 (299) has been used for this purpose. 
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5.2 Methods 
Untreated control (C ): isolated hearts were stabilized for 60 min (15 min retrograde perfusion, 15 
min working heart mode, 30 min retrograde perfusion) before 20 min sustained global ischaemia or 
35 min regional ischaemia followed by 30 min reperfusion (10 min retrograde, 20 min working heart ) 
(protocol III: 1, 6) 
Drug treatment (protocol III) 
(1). After isolated hearts had been stabilized for 50 min (15 min retrograde, 15 min working heart 
mode, then perfused retrogradely 20 min), dexamethasone(1 µM) was added for 10 min before 20 
min sustained global ischaemia or 35 min regional ischaemia followed by 30 min reperfusion 
(Pre+Dex, protocols 2, 7). 
(2). Isolated hearts were stabilized for 60 min (15 min retrograde, 15 min working heart mode, then 
perfused retrogradely 30 min), then subjected to 20 min sustained global ischaemia or 35 min 
regional ischaemia followed by 15 min retrograde reperfusion in the presence of dexamethasone(1 
µM) and 20 min reperfusion in the working model (Rep+Dex, protocols 3, 8). 
(3). In one series of experiments, dexamethasone (3mg/kg/day) or an equivalent volume of saline 
was administered intraperitoneally to the rats for 10 days. After anaesthesia, hearts were removed 
from rats and stabilized on the perfusion rig for 60 min folowed by 20 min sustained global 
ischaemia or 35 min regional ischaemia and 30 min reperfusion as described above (ip Dex and ip 
Sal, protocols 4, 5). 
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5.3 Results 
5.3.1 Effect of dexamethasone on cardiac mechanical recovery. 
Table 5 shows that dexamethasone (3mg/kg daily) administered intraperitoneally to the rats for 10 
days before experimentation (ip Dex) or dexamethasone(1 µM) added for 10 min before (Pre+Dex) 
or 15 min after (Rep+Dex) 20 min sustained global ischaemia, resulted in a significant increase in 
all parameters of post-ischaemic functional recovery (CF, AO, CO, Psp, HR,TW) during 30 min 
reperfusion (Fig 15), when compared with values obtained from untreated control hearts (p < 0.05, 
for all parameters). More surprisingly, in ip Dex protocol, all parameters of functional recovery 
during 30 min reperfusion were increased so markedly that they were not only significantly different 
from untreated control values (p < 0.05), but were similar to those obtained before subjecting hearts 
to sustained ischaemia (p > 0.05). Please note that the reperfusion time of hearts treated with 
dexamethasone during reperfusion, averaged 35 min (rather than 30 min as in other groups).  
5.3.2 Effect of dexamethasone on infarct size  
Infarct size is expressed as a percentage of the area at risk in rat hearts. Dexamethasone (1µM), 
when added for 10 min before (Pre+Dex) or 15 min after (Rep+Dex) 35 min regional ischaemia, 
significantly reduced infarct size to 20.5±1.3% and 25.4±1.52%, respectively, from 36.2±2.1% in 
untreated control hearts (p < 0.05, Fig 16). In these studies, the area at risk did not differ between 
the groups. The averaged value was 46.8±4.3%. 
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Abbreviations: as in Table 2. C=control
Pre+Dex: dexamethasone added before sustained ischaemia.
Rep+Dex: dexamethasone added during reperfusion
ip Sal: intraperitoneal saline before experiment 
ip Dex: intraperitoneal dexamethasone before experiment
Data are means ± SE, n ≥6 per group. Protocol III.
Effect of dexamethasone (1µM) on functional recovery 
during reperfusion after 20 min sustained global ischaemia. 
Table 5
10.89±0.63*#259±9*#98±1*#53.7±1.3*#36.8±1.1*#16.8±0.48*#ip Dex
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5.38±1.42 *†244±13 * 85±10 * 26.3±6.1 *†16±5.6 *†10.3±0.7 *†Rep+Dex
8.64±0.77 *†253±4 * 95±4 * 40.7±2.1*†28.5±1.9 *†12.2±0.58 * Pre+Dex
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5.3.3 Effects of dexamethasone on expression of MKP-1 and kinase activation. 
Regardless of the mode of dexamethasone administration ( intraperitoneal 3 mg/kg daily for 10 
days (ip Dex) or added (1µM) for 10 min before (Pre+Dex) or 15 min after (Rep+Dex) 20 min 
sustained global ischaemia), a marked increase in MKP-1 expression was observed after 30 min 
reperfusion when compared with untreated controls (a.u ip-Dex: 1.51±0.09, Pre+Dex: 4.11±0.36, 
Rep+Dex: 1.51±0.07 vs. C: 1.00, p < 0.05, respectively. Fig. 17). However, after 5 min reperfusion, 
no MKP-1 expression could be seen in hearts pretreated for 10 min with dexamethasone (1µM). 
In ip-Dex and Pre+Dex protocols, a significant decrease in p38 MAPK phosphorylation during 
reperfusion was observed versus untreated controls (a.u Pre+Dex: 5 min 0.53±0.10 and 30 min 
0.41±0.08; ip-Dex: 30 min 0.32±0.16, respectively, p < 0.05, Fig. 18).  
In Pre+Dex protocol, after 5 min reperfusion, an increased phosphorylation of ERK42/44 was seen 
(a.u 1.42±0.19/1.91±0.48), but only ERK44 activity was significantly elevated (1.91±0.48 vs. 1.00 in 
untreated control, p < 0.05, Fig 19). However, after 30 min reperfusion, no marked change in 
ERK42/44 phosphorylation was observed. Also in this protocol, dexamethasone had no effect on 
PKB phosphorylation after 5 min reperfusion (a.u 1.19±0.21, Fig 20). In ip-Dex protocol, there was 
also no significant difference in ERK42/44 activity after 30 min reperfusion.  
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5.4 Discussion 
The results obtained in this study showed clearly that dexamethasone, whether administered 
intraperitoneally for 10 days before experimentation or directly added to the perfusate of the isolated 
heart, afforded significant protection against ischaemia/reperfusion damage. The significant 
upregulation of MKP-1 occurring during reperfusion, suggests a role for this phosphatase in 
dexamethasone-mediated cardioprotection. 
 
Induction of MPK-1 by dexamethasone in the working heart model appears to be time-dependent.  
Regardless of the mode of dexamethasone administration, after 5 min reperfusion, no MPK-1 
expression could be seen, but after 30 min reperfusion, a marked increase in MPK-1 expression 
was observed. This led us to conclude that the ability of dexamethasone to induce MKP-1 
expression is time-dependent. However, a reduction in p38 MAPK phosphorylation during 
reperfusion is evident before upregulation of MKP-1 is visible (Fig 17,18). A similar time-dependent 
effect was observed in a mast cell line, where dexamethasone induced MKP-1 expression after 5h 
(300). 
 
Effects of glucocorticords: 
It has long been known that dexamethasone protects against ischaemia/reperfusion damage. It was 
first shown in 1980 by Lefer et al (301) that dexamethasone normalized ST-segment elevation and 
reduced necrosis in cats subjected to coronary artery ligation. Similarly, Bernauer (302) showed that 
dexamethasone inhibited myocardial necrosis in rats, with and without reperfusion after ischaemia. 
At the time, this was suggested to be due to de novo synthesis of macrocortin, an 
antiphospholipase protein (303). The cardioprotective effects of the glucocorticoid, 
methylprednisolone, were investigated by Valen and coworkers. Her studies suggested roles for 
HSP72 (304) as well increased tissue antioxidant activity (305) during reperfusion as mediators for 
cardioprotection. Engelman and coworkers (306) showed that steroid-induced myocardial 
preservation was associated with decreased membrane microviscosity. The anti-inflammatory 
actions of dexamethasone have been shown to block sepsis-induced protection of the heart from 
ischaemia-reperfusion injury (307). The contribution of dexamethasone treatment to the recovery of 
postischaemic cardiac function was also studied by Varga and coworkers (308). In their study, rats 
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were treated with dexamethasone 24 h before being subjected to 30 min global ischaemia and 120 
min reperfusion. Dexamethasone pretreatment significantly reduced the occurrence of ventricular 
fibrillation, and release of cytochrome C, while increasing postischaemic function. In their study 
actinomycin D inhibited the cardioprotective effects of dexamethasone, probably by inhibiting RNA 
synthesis. However, despite the above studies, the mechanism of the beneficial effects of 
dexamethasone pretreatment still remains unclear. It is possible that the changes observed by the 
above workers, are merely events associated with cardioprotection (or epiphenomena) and not the 
cause. 
Glucocorticoids influence a great variety of cellular functions, for example, the repression (309) or 
activation of genes (310, 311), the induction of apoptosis (312) or protection from apoptosis (312). 
Another possible mechanism for glucocorticoid action, which may be particularly important in the 
setting of ischaemia/reperfusion, is the fact that it significantly inhibits MAPK signalling. This effect 
requires gene induction, possibly of a MAPK phosphatase (MKP) which could inhibit both 
transcriptional and posttranscriptional mechanisms controlled by the MAP kinases. For example, it 
has been shown that glucocorticoids inhibit ERK 1/2 activation via increased expression and 
decreased proteasomal degradation of MKP-1 (300). 
 
MKP-1 actions: 
It has been suggested that the dual-specificity phosphatase MKP-1 may function as a critical 
anti-apoptotic regulator. Overexpression of MKP-1 is associated with decreased apoptosis, 
suggesting that MKP-1 overexpression may be causally linked to the prevention of cardiomyocyte 
apoptosis (313, 314). MKP-1 can be induced by growth factors (305), oxidative stress (316), 
arachidonic acid (317), and 12-O-tetradecanoylphorbol-13-acetate (318) and is regulated at the 
transcriptional level. The expression of MKP-1 in response to dexamethasone is sustained, in 
contrast to the transient induction by growth factors and cellular stresses demonstrated elsewhere 
(71, 319, 320). However, the mechanism(s) of inhibition of MKP-1 degradation by glucocorticoids is 
still unknown. It is possible that MKP-1 exerts beneficial effects on the heart via inactivation of the 
MAP kinases, p38 MAPK in particular. The harmful effects of this kinase in ischaemia/reperfusion 
has been reviewed by Steenbergen et al (295). Originally isolated as a stress-responsive protein 
phosphatase, MKP-1 was initially shown to dephosphorylate ERK (319, 321). A combination of in 
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vitro and overexpression studies in cultured cells subsequently demonstrated that MKP-1 
dephosphorylated the MAPKs with a rank order of p38 MAPK > JNK > ERK (76-78). In turn, MKP-1 
may be catalytically activated by p38 MAPK (70). These observations suggest the participation of 
MKP-1 in a complex feedback loop which modulates p38 MAPK activity.  
 
Although these studies supported the interpretation that MKP-1 has a higher potency of 
dephosphorylation toward the stress-responsive MAPKs, it remained unclear whether MKP-1 was 
absolutely required for the physiological inactivation of these MAPKs. Studies using mice in which 
MKP-1 expression was disrupted (322), suggested that MKP-1 plays a redundant role in the 
regulation of ERK activity and cell growth. 
 
In the present study, we demonstrate that under our experimental circumstances dexamethasone 
significantly improved post-ischaemic cardiac functional recovery and reduced infarct size 
associated with a marked increase in MKP-1 expression and decrease of p38 MAPK 
phosphorylation after 30 min reperfusion. Based on a report from Zhao et al. (323) who 
demonstrated that macrophages isolated from MKP-1-deficient mice exhibited hyperactivation of 
ERK, JNK, and p38 MAPK in response to lipopolysaccharide stimulation in the livers of 
MKP-1-deficient mice. We propose that dexamethasone-induced MKP-1 regulation is responsible 
for dephosphorylation of p38 MAPK in particular. Thus, these data suggest that MKP-1 plays a 
critical role in the negative regulation of p38 MAPK in response to ischaemia/referfusion to promote 
cell survival.  
 
However, in our system, the PKB/Akt phosphorylation level was not affected by dexamethasone 
treatment suggesting that the PI3K-Akt pathway is not involved in dexamethasone protection 
against ischaemia/reperfusion damage. As far as we know, MKP-1 does not dephosphorylate 
PKB/Akt. In contrast to previous reports, the upregulation of MKP-1 was not associated with a 
reduced phosphorylation of ERK42/44 (76-78). 
 
Studies in other cell types have also indicated that p38 MAPK is the preferred substrate for MKP-1 
(77). On the other hand, other MAPK, such as JNK has also been identified as targets for negative 
regulation by glucocorticoids (324-327). Glucocorticoid-mediated inhibition of JNK occurs after a 
Stellenbosch University http://scholar.sun.ac.za
 86
short time of hormone treatment (324, 326), does not require new protein synthesis and is 
independent of the transactivation function of the glucocorticoid receptor (324). JNK has not been 
studied in our model. The inhibition of p38, on the other hand, occurs after a short time of treatment 
with glucocorticoids but requires de novo protein expression (327). 
 
In contrast to the above, other investigators have reported that dexamethasone either has no effect 
(325, 328) or causes a modest inhibition (329) or activates p38 MAPK (330). These contrasting 
observations presumably reflect cell-specific differences in the cross talk between the glucocorticoid 
and p38 signalling pathways. 
 
However, according to our data, MKP-1 plays a critical role in the inactivation of p38 MAPK. 
Furthermore, the data presented here are in line with those recently published providing strong 
support for the conclusion that MKP-1 is a critical factor in the attenuation of p38 MAPK activity in 
neonatal cardiomyocytes exposed to hypoxia/reoxygenation (298). 
 
Summary 
The results of this study demonstrated that the glucocorticoid, dexamethasone, improved 
post-ischaemic cardiac functional recovery, reduced infarct size associated with increased 
expression of MKP-1 and ERK44 phosphorylation and suppressed phosphorylation of p38 MAPK. 
We conclude that glucocorticoids play an important modulatory role in the regulation of reactive 
signalling pathways in cardiac myocytes in ischaemia/reperfusion. To our knowledge, this is the first 
demonstration that the well-known cardiac actions of dexamethasone can be attributed to 
upregulation of the phosphatase MKP-1. 
 
The specific upregulation of endogenous dual-specificity phosphatases in the heart might offer an 
additional therapeutic strategy to benefit certain forms of heart disease. From a therapeutic point of 
view, our understanding of the molecular mechanisms regulating MAPK and MAPK phosphatase 
activities by glucocorticoids could lead to new strategies for the effective prevention and control of 
heart disease.  
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Chapter 6 
 
Conclusion 
 
Since the first report on the phenomenon of ischaemic preconditioning more than two decades ago, 
many articles have appeared, characterizing the phenomenon in different animal species, as well 
as attempting to elucidate its mechanism. Although unravelling the final steps in the mechanism of 
protection has not been successful thus far, our knowledge regarding signalling events in the 
ischaemic/reperfused heart has increased exponentially over the last years. As described in 
Chapter I, the focus of research has been mainly on the role of kinases in this scenario, while very 
little indeed is known about the contributions of the phosphatases. The chief objective of this study 
has therefore been to gain more information about the significance of the phosphatases in the 
setting of ischaemia/reperfusion and ischaemic preconditioning. 
 
A number of interesting and possibly significant observations were made: 
 
(i) PSP and PP1 activation, as measured by an in vitro assay, does not change during either a 
relatively long period of global ischaemia or during reperfusion; moreover, no difference could be 
discerned in the phosphatase activity of tissues obtained from non-preconditioned and 
preconditioned hearts. This could be due to the relatively short periods of reperfusion.  
 
(ii) Despite the above negative results, indications are that phosphatases play a significant role in 
the preconditioning protocol: administration of the phosphatase inhibitors, cantharidin or okadaic 
acid during the preconditioning phase completely abolished cardioprotection, as evidenced by 
mechanical failure during reperfusion, increased infarct size and activation of p38 MAPK and PKB, 
and dephosphorylation of ERK42/44; but inhibition of PP1 and PP2A during reperfusion after 
sustained global ischaemia in preconditioned hearts increased cardioprotection, particularly in the 
case of hearts subjected to 3x5 min preconditioning, associated with increased phosphorylation of 
the RISK pathway, and dephosphorylation of p38 MAPK. Non-specificity of inhibitors also may be 
the limitation of this study. 
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(iii) Upregulation of the phosphatase MKP-1 is cardioprotective. The phosphatase MKP-1 
selectively inactivates p38 MAPK by dephosphorylation of the regulatory Thr and Tyr residues. We 
demonstrate that under our experimental circumstances the glucocorticoid, dexamethasone, 
improved functional recovery, reduced infarct size associated with upregulation of the MKP-1 and 
dephosphorylation of the pro-apoptotic p38 MAPK during reperfusion. These data suggest that 
MKP-1 plays a critical role in the negative regulation of p38 MAPK in response to 
ischaemia/reperfusion to promote cell survival.  
 
The finding that inhibition of PP1 and PP2A during the preconditioning phase completely abolished 
cardioprotection suggests that the transient activation of p38 MAPK which occurs during a 
multi-cycle preconditioning phase (242) may be due to dephosphorylation induced by these 
phosphatases. Administration of okadaic acid, which specifically inhibits PP2A, suggests a role for 
this particular phosphatase in the phenomenon of preconditioning. 
 
As far as we know, this is the first demonstration that manipulation of the RISK pathway by 
phosphatase inhibition during reperfusion is associated with cardioprotection. 
 
The cardioprotective effects of dexamethasone have been described before, but the present study 
is the first demonstration that this is associated with upregulation of the phosphatase MKP-1 and 
dephosphorylation of p38 MAPK. However, the significance of the RISK pathway as a target for 
phosphatase manipulation and the end-effectors involved, need further investigation. 
 
Thus manipulation of the pro-survival PI3K–Akt and MEK1/2–ERK1/2 kinase cascades during the 
early reperfusion by administration of phosphatase inhibitors has great promise for new 
pharmacological approaches to reduce the morbidity and mortality of ischaemic heart disease. 
However, the data presented in this study have merely scratched the surface of what potentially 
may be a promising new approach. Not only should a thorough study be made of the phosphatases 
involved, but also of the factors involved in their regulation. More sophisticated experimental 
approaches are required, for example, use of knockout or transgenic animals or the siRNA 
technique. 
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